Clinical trial register · France

Clinical Trials in Lyon, 2026

Every study on the ClinicalTrials.gov registry that lists a site in France and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV

Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage — all 9697 matching records held by the registry are in this view. Synced 26 Oct 2026, 03:20 UTC

9697

Studies in scope

all four open statuses

6025

Recruiting now

open to new participants

1033

Lead sponsors

across recruiting studies

Top sites

Paris 2821 Lyon 1392 Bordeaux 1389 Marseille 1285 Lille 1282

Trials with a site in Lyon

Status

Study

Lead sponsor

Phase

Enrol

Sites in France

Start

Active, closed

Anti-PD-1 and mDCF Followed by Chemoradiotherapy in Patients With Stage III Squamous Cell Anal Carcinoma.

NCT04719988Squamous Cell Carcinoma of the Anus Stage III

DrugBlood sample collection

Centre Hospitalier Universitaire de Besancon

Phase 2

Besançon, Dijon, Levallois-Perret, Lyon, Montbéliard, Nice, Paris, Poitiers

2022-01-04

Recruiting

A Study of Zidesamtinib (NVL-520) in Patients With Advanced NSCLC and Other Solid Tumors Harboring ROS1 Rearrangement (ARROS-1)

NCT05118789Locally Advanced Solid Tumor, Metastatic Solid Tumor

Nuvalent Inc.

Phase 1/2

359

Lyon, Nantes, Toulouse, Villejuif

2022-01-04

Recruiting

Efficiency of Imatinib Treatment After 10 Years of Treatment in Patients With Gastrointestinal Stromal Tumours (GIST) (Gist-Ten)

NCT05009927Metastatic Gastrointestinal Stromal Tumor (GIST), C-KIT Mutation, Advanced Gastrointestinal Stromal Tumor (GIST)

DrugsGlivec·Imatinib

Centre Leon Berard

Phase 2

Besançon, Bordeaux, Limoges, Lyon, Marseille, Paris, Reims, Rennes

2022-01-03

Recruiting

Randomized, Multicenter, Phase III Trial to Assess Conformal Post-operative Radiotherapy vs. Surveillance After Complete Resection of Stage II/III Thymoma (RADIO-RYTHMIC-01)

NCT04731610Thymoma Malignant Recurrent

Institut Curie

Not applicable

314

Caen, Dijon, Lille, Lyon, Marseille, Montpellier, Nice, Paris

2021-12-28

Recruiting

Prodromes of Menstrual Staphylococcal Toxic Shock

NCT06124599Toxic Shock Syndrome Staphylococcal

Hospices Civils de Lyon

Observational

316

Lyon

2021-12-21

Active, closed

Lutetium 177Lu-Edotreotide Versus Best Standard of Care in Well-differentiated Aggressive Grade-2 and Grade-3 GastroEnteroPancreatic NeuroEndocrine Tumors (GEP-NETs) - COMPOSE

NCT04919226Neuroendocrine Tumors

DrugsFOLFOX (Folinic acid·Everolimus·Fluorouracil·Oxaliplatin

ITM Solucin GmbH

Phase 3

259

Pessac, Nantes, Lyon, Toulouse

2021-12-21

Active, closed

A Study of Selpercatinib After Surgery or Radiation in Participants With Non-Small Cell Lung Cancer (NSCLC)

NCT04819100Carcinoma, Non-Small-Cell Lung

DrugSelpercatinib

Eli Lilly and Company

Phase 3

152

Lyon, Marseille, Rouen, Le Plessis-Robinson, Villejuif, Paris

2021-12-20

Active, closed

A Study Evaluating the Efficacy and Safety of Mitapivat in Participants With Non-Transfusion-Dependent Alpha- or Beta-Thalassemia (α- or β-NTDT)

NCT04770753Non-Transfusion-dependent Alpha-Thalassemia, Non-Transfusion-dependent Beta-Thalassemia

DrugMitapivat

Agios Pharmaceuticals, Inc.

Phase 3

194

Créteil, Lyon

2021-12-20

Active, closed

Treatment With Tucatinib in Patients With an Isolated Brain Progression of a Metastatic Breast Cancer

NCT05041842Metastatic Breast Cancer With a Isolated Brain Progression

DrugsPertuzumab/Trastuzumab·Phesgo·Perjeta·Tucatinib

UNICANCER

Phase 2

Angers, Bordeaux, Caen, Dijon, Le Mans, Lyon, Montpellier, Nice

2021-12-17

Active, closed

Study to Assess the Efficacy and Safety of Alpelisib Plus Fulvestrant in Participants With HR-positive (HR+), HER2-negative, Advanced Breast Cancer After Treatment With a CDK4/6 Inhibitor and an Aromatase Inhibitor.

NCT05038735Breast Cancer

DrugsAlpelisib·Fulvestrant

Novartis Pharmaceuticals

Phase 3

210

Besançon, Clermont-Ferrand, La Roche-sur-Yon, Lyon, Marseille, Montpellier, Paris, Valenciennes

2021-12-17

Recruiting

A Study of Elritercept Alone or Together With Ruxolitinib in Adults With Myelofibrosis

NCT05037760Myelofibrosis

DrugsElritercept·Ruxolitinib

Takeda

Phase 2

135

Amiens, Brest, Cesson-Sévigné, Lyon, Nîmes, Orléans

2021-12-16

Recruiting

Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid Tumors

NCT05176483Renal Cell Carcinoma (RCC), Metastatic Castration-Resistant Prostate Cancer (mCRPC), Urothelial Carcinoma (UC), Solid Tumor

DrugsZanzalintinib·Relatlimab·Yervoy·Ipilimumab

Exelixis

Phase 1

1,394

Besançon, Bordeaux, Caen, Clermont-Ferrand, Lyon, Marseille, Nice, Paris

2021-12-14

Active, closed

Long-term Follow-up Study to Evaluate Durability of Treatment Response in Previous Bepirovirsen Study Participants (B-Sure)

NCT04954859Hepatitis B

DrugBepirovirsen

GlaxoSmithKline

Phase 2

360

Clichy, Lyon, Paris, Pessac, Rennes, Strasbourg

2021-12-14

Active, closed

BONAPH1DE, A Prospective Observational Study of Patients With Primary Hyperoxaluria Type 1 (PH1)

NCT04982393Primary Hyperoxaluria Type 1

Alnylam Pharmaceuticals

Observational

207

Bordeaux, Lyon, Paris

2021-12-13

Recruiting

JNJ-90301900 (NBTXR3) Activated by Radiotherapy With or Without Cetuximab in LA-HNSCC

NCT04892173Carcinoma, Squamous Cell

DrugsJNJ-90301900·Erbitux·Cetuximab

Johnson & Johnson Enterprise Innovation Inc.

Phase 3

500

Amiens, Brest, Caen, Dijon, Lille, Lyon, Marseille, Neuilly-sur-Seine

2021-12-10

Recruiting

First-in-Human Study of Mutant-selective PI3Kα Inhibitor, RLY-2608, as a Single Agent in Patients With Advanced Solid Tumors and in Combination With Endocrine Therapy +/- a CDK4/6 or CDK4 Inhibitor in Patients With Advanced Solid Tumors or Advanced Breast Cancer

NCT05216432PIK3CA Mutation, Solid Tumor, Adult, HER2-negative Breast Cancer, Breast Cancer

DrugsRLY-2608·Atirmociclib·Ribociclib·Palbociclib

Relay Therapeutics, Inc.

Phase 1

930

Lyon, Bordeaux, Villejuif

2021-12-08

Active, closed

Short-term Pre-OPerative Durvalumab (MEDI 4736) in Early Small Triple Negative Breast Cancer Patients (POP-Durva)

NCT05215106Early Small (cT1N0) Triple Negative Breast Cancer

DrugDurvalumab

Gustave Roussy, Cancer Campus, Grand Paris

Phase 2

200

Bordeaux, Lyon, Villejuif

2021-12-06

By invitation

Extension Study of Infigratinib in Children With Achondroplasia (ACH)

NCT05145010Achondroplasia

DrugInfigratinib

QED Therapeutics, a BridgeBio company

Phase 2

300

Lyon, Paris, Toulouse

2021-12-06

Active, closed

A Study of Zanidatamab in Combination With Chemotherapy Plus or Minus Tislelizumab in Patients With HER2-positive Advanced or Metastatic Gastric and Esophageal Cancers

NCT05152147Gastric Neoplasms, Gastroesophageal Adenocarcinoma, Esophageal Adenocarcinoma

DrugsZanidatamab·Herceptin·Trastuzumab·Adrucil

Jazz Pharmaceuticals

Phase 3

920

Pessac, Avignon, Bordeaux, Dijon, Grenoble, Lyon, Nantes, Poitiers

2021-12-02

Active, closed

A Study Evaluating the Efficacy and Safety of Mitapivat in Participants With Transfusion-Dependent Alpha- or Beta-Thalassemia (α- or β-TDT)

NCT04770779Transfusion-dependent Alpha-Thalassemia, Transfusion-dependent Beta-Thalassemia

DrugMitapivat

Agios Pharmaceuticals, Inc.

Phase 3

258

Créteil, Lyon, Marseille, Paris

2021-11-30

Recruiting

Identification of Dysglycemia With Continuous Glucose Monitoring to Assess Clinical Evolution in Cystic Fibrosis

NCT05099939Cystic Fibrosis

Institut de Recherches Cliniques de Montreal

Observational

121

Lyon, Strasbourg

2021-11-25

Active, closed

Registry for Patients Undergoing Penile Prosthesis Implantation for Male Erectile Dysfunction

NCT03849586Erectile Dysfunction

European Association of Urology Research Foundation

Observational

1,076

Lyon

2021-11-19

Active, closed

Efficacy and Safety of Selumetinib in Adults With NF1 Who Have Symptomatic, Inoperable Plexiform Neurofibromas

NCT04924608Neurofibromatosis 1, Plexiform Neurofibroma (PN)

DrugSelumetinib

AstraZeneca

Phase 3

145

Créteil, Lyon, Toulouse

2021-11-19

Recruiting

Refining Adjuvant Treatment IN Endometrial Cancer Based On Molecular Features

NCT05255653Endometrial Cancer

DrugDurvalumab

Leiden University Medical Center

Phase 3

316

Besançon, Bordeaux, Lyon, Marseille, Montpellier, Nice, Saint-Herblain, Strasbourg

2021-11-11

Active, closed

Long-term Performance and Safety of Biodentine™ in Patients Treated for Endodontic Indications

NCT05084742Endodontically Treated Teeth

Septodont

Observational

145

Colombes, Lyon, Nantes, Paris, Reims, Toulouse

2021-11-08

Active, closed

A Study to Investigate the Efficacy and Safety of Trastuzumab Deruxtecan as the First Treatment Option for Unresectable, Locally Advanced/Metastatic Non-Small Cell Lung Cancer With HER2 Mutations

NCT05048797Locally Advanced or Metastatic Non-Small Cell Lung Cancer

DrugsTrastuzumab deruxtecan·Pemetrexed·Cisplatin·Carboplatin

AstraZeneca

Phase 3

454

Bordeaux, Dijon, Le Mans, Lyon, Marseille, Nantes, Toulouse, Villejuif

2021-10-28

Active, closed

Immunotherapy Clearance and Phenotype of Circulating Tumor Cells in Lung and Head and Neck Cancers

NCT05091190Metastatic NSCLC, Metastatic Head and Neck Cancer

Hospices Civils de Lyon

Not applicable

Lyon, Pierre-Bénite

2021-10-27

Recruiting

First in Human Study of BAY2927088 in Participants Who Have Advanced Non-small Cell Lung Cancer (NSCLC) With Mutations in the Genes of Epidermal Growth Factor Receptor (EGFR) and/or Human Epidermal Growth Factor Receptor 2 (HER2)

NCT05099172Advanced Non-small Cell Lung Cancer, EGFR Mutation, HER2 Mutation

Bayer

Phase 1/2

430

Lyon, Bordeaux, Nantes, Saint-Herblain, Marseille, Paris, Villejuif

2021-10-25

Active, closed

A Trial to Assess Efficacy and Safety of Octreotide Subcutaneous Depot in Patients With GEP-NET

NCT05050942Gastro-enteropancreatic Neuroendocrine Tumor

DrugsCAM2029·Octreotide LAR

Camurus AB

Phase 3

332

Bordeaux, Chambray-lès-Tours, Dijon, Lille, Lyon, Nantes, Rennes, Strasbourg

2021-10-22

Active, closed

Immunotherapy in MSI/dMMR Tumors in Perioperative Setting.

NCT04795661Localized Resectable Tumor, MSI/dMMR

DrugPembrolizumab

Centre Leon Berard

Phase 2

240

Amiens, Clermont-Ferrand, Dijon, Lille, Lyon, Marseille, Montpellier, Nice

2021-10-18

Active, closed

A Phase-3, Open-Label, Randomized Study of Dato-DXd Versus Investigator's Choice of Chemotherapy (ICC) in Participants With Inoperable or Metastatic HR-Positive, HER2-Negative Breast Cancer Who Have Been Treated With One or Two Prior Lines of Systemic Chemotherapy (TROPION-Breast01)

NCT05104866Breast Cancer

DrugsEribulin·Dato-DXd·Vinorelbine·Capecitabine

AstraZeneca

Phase 3

732

Bezannes, Bordeaux, Lille, Lyon, Montpellier, Plérin, Toulouse, Villejuif

2021-10-18

Active, closed

A Study of Teclistamab in Combination With Daratumumab Subcutaneously (SC) (Tec-Dara) Versus Daratumumab SC, Pomalidomide, and Dexamethasone (DPd) or Daratumumab SC, Bortezomib, and Dexamethasone (DVd) in Participants With Relapsed or Refractory Multiple Myeloma

NCT05083169Multiple Myeloma

DrugsTeclistamab·Pomalidomide·Bortezomib·Daratumumab

Janssen Research & Development, LLC

Phase 3

587

Créteil, Lille, Limoges, Lyon, Nantes, Poitiers, Strasbourg, Toulouse

2021-10-14

Active, closed

Study of Vimseltinib for Tenosynovial Giant Cell Tumor

NCT05059262Tenosynovial Giant Cell Tumor, Pigmented Villonodular Synovitis, Giant Cell Tumor of Tendon Sheath, Tenosynovial Giant Cell Tumor, Diffuse

DrugVimseltinib

Deciphera Pharmaceuticals, LLC

Phase 3

123

Bordeaux, Lyon, Villejuif

2021-10-14

Recruiting

Evaluation of the Efficiency of the Bone Substitute Cerament-G Locally Delivering Gentamicin in the Treatment of Chronic Osteomyelitis of Long Bones

NCT04805164Osteomyelitis Chronic

Hospices Civils de Lyon

Not applicable

220

Amiens, Besançon, Bordeaux, Boulogne-Billancourt, Brest, Caen, Lille, Lyon

2021-10-14

Active, closed

Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 as Monotherapy and in Combination With IV Bevacizumab

NCT05029882Non-Small Cell Lung Cancer, Advanced Solid Tumors, Gastroesophageal Adenocarcinoma, Colorectal Cancer

DrugsTelisotuzumab Adizutecan·Trifluridine/Tipiracil·Bevacizumab

AbbVie

Phase 1

520

Bordeaux, Saint-Herblain, Nice, Lyon, Villejuif, Dijon, Paris

2021-10-13

Recruiting

Evaluation of the Long-term Therapeutic Effect of High-Intensity Focused Ultrasound (HIFU) Treatment in Patients With Rectal Endometriosis

NCT07179419Endometriosis

EDAP TMS S.A.

Observational

140

Lyon

2021-10-10

Recruiting

Add-on Buprenorphine at Analgesic Doses for the Treatment of Severe Suicidal Ideas During a Major Depressive Episode

NCT03646058Suicidal Ideation, Major Depressive Episode

DrugBuprenorphine

Centre Hospitalier Universitaire de Nīmes

Phase 3

180

Bordeaux, Le Kremlin-Bicêtre, Lyon, Nantes, Nîmes, Paris, Poitiers, Toulouse

2021-10-10

Active, closed

Observational GORE® VIABAHN® Endoprosthesis With PROPATEN Bioactive Surface Global Registry

NCT04907240Peripheral Artery Disease, Popliteal Aneurysm, Hemodialysis Access, Visceral Artery Aneurysms

W.L.Gore & Associates

Observational

614

Angers, Brest, Lyon, Paris, Strasbourg

2021-10-09

Active, closed

A Study Evaluating the Efficacy and Safety of Biomarker-Driven Therapies in Patients With Persistent or Recurrent Rare Epithelial Ovarian Tumors

NCT04931342Ovarian Cancer

DrugsCobimetinib·Ipatasertib·Giredestrant·Inavolisib

Hoffmann-La Roche

Phase 2

176

Besançon, Caen, Lyon, Paris, Rennes, Saint-Herblain, Toulouse, Villejuif

2021-10-07

Active, closed

Study on an Investigational Yellow Fever Vaccine Compared With Stamaril in Adults in Europe and Asia

NCT05011123Yellow Fever

DrugYellow fever vaccine

Sanofi Pasteur, a Sanofi Company

Phase 2

690

Lyon, Montpellier, Nantes, Nîmes, Paris, Pierre-Bénite

2021-10-07

Active, closed

A Study of Oral Asciminib Versus Other TKIs in Adult Patients With Newly Diagnosed Ph+ CML-CP

NCT04971226Chronic Myeloid Leukemia (CML) Philadelphia Chromosome Positive

DrugsBosutinib·Asciminib·ABL001·Nilotinib

Novartis Pharmaceuticals

Phase 3

405

Bordeaux, Lyon, Nantes, Paris

2021-10-06

Active, closed

Evaluating a Health Literacy Intervention to Improve Colorectal Cancer Screening in Underserved Areas

NCT04631692Colorectal Cancer Screening

University Paul Sabatier of Toulouse

Not applicable

1,025

Lyon, Marseille, Paris, Toulouse

2021-10-01

Active, closed

Single-stage Surgery With Antibiotic-loaded Hydrogel Coated Implants Versus Two Stage Surgery for Secondary Prevention of Complex Chronic Periprosthetic Hip Joint Infection

NCT04251377Hip Prosthesis Infection

Centre Hospitalier Universitaire de Saint Etienne

Not applicable

Amiens, Bordeaux, Caen, Clermont-Ferrand, Dijon, Lille, Lyon, Marseille

2021-09-30

Active, closed

A Study to Compare the Efficacy and Safety of Entrectinib and Crizotinib in Participants With Advanced or Metastatic ROS1 Non-small Cell Lung Cancer (NSCLC) With and Without Central Nervous System (CNS) Metastases

NCT04603807Carcinoma, Non-Small-Cell Lung

DrugsEntrectinib·Crizotinib

Hoffmann-La Roche

Phase 3

217

Bordeaux, Lille, Lyon, Marseille, Rennes, Toulouse, Vantoux

2021-09-30

Active, closed

Study of INBRX-109 in Conventional Chondrosarcoma

NCT04950075Conventional Chondrosarcoma

DrugINBRX-109

Inhibrx Biosciences, Inc

Phase 2

206

Bordeaux, Lille, Lyon, Marseille, Montpellier, Nice, Paris, Rennes

2021-09-23

Active, closed

Safety and Efficacy of Mitazalimab in Combination With Chemotherapy in Pancreatic Cancer Patients

NCT04888312Metastatic Pancreatic Ductal Adenocarcinoma

DrugMitazalimab

Alligator Bioscience AB

Phase 1/2

Bordeaux, Lyon, Marseille, Paris, Vandœuvre-lès-Nancy

2021-09-17

Active, closed

REZŪM vs. Dual Drug Therapy for Symptomatic Benign Prostatic Hyperplasia in Sexually Active Men

NCT04838769Benign Prostatic Hyperplasia (BPH)

Boston Scientific Corporation

Not applicable

155

Aix-en-Provence, Angers, Bordeaux, Grenoble, Lille, Lyon, Nice, Paris

2021-09-15

Active, closed

A Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Alectinib in Pediatric Participants With ALK Fusion-Positive Solid or CNS Tumors

NCT04774718ALK Fusion-positive Solid or CNS Tumors

DrugAlectinib

Hoffmann-La Roche

Phase 1/2

Lyon, Marseille, Paris

2021-09-14

Recruiting

Intestine-lung Axis of Cystic Fibrosis Patients Treated With the Combination Elexacaftor/Tezacaftor/Ivacaftor

NCT05937815Cystic Fibrosis

University Hospital, Bordeaux

Not applicable

253

Bordeaux, Grenoble, Lille, Limoges, Lyon, Marseille, Montpellier, Nancy

2021-09-13

Recruiting

A Dose-Escalation and Expansion Study of Tacabrutideg (BGB-16673) in Participants With B-Cell Malignancies

NCT05006716B-cell Malignancy, Marginal Zone Lymphoma, Follicular Lymphoma, Non-Hodgkin Lymphoma

DrugTacabrutideg

BeOne Medicines

Phase 1/2

689

Bordeaux, ClermontFerrand, Créteil, Lille, Lyon, Marseille, Montpellier, Paris

2021-09-13

Recruiting

Perform Humeral System Study

NCT05067543Osteoarthritis Shoulder, Avascular Necrosis, Post-traumatic Arthrosis of Other Joints, Shoulder Region, Rotator Cuff Tear Arthropathy

Stryker Trauma and Extremities

Observational

300

Lyon

2021-09-12

Active, closed

Safety, Tolerability, Pharmacokinetics and Efficacy Study of Radotinib in Parkinson's Disease

NCT04691661Parkinson Disease

DrugRadotinib HCl

Il-Yang Pharm. Co., Ltd.

Phase 2

Lille, Limoges, Lyon, Nantes, Paris, Poitiers, Rouen

2021-09-09

Active, closed

A Study of Guselkumab and Interleukin-17 (IL-17) Inhibitor Therapies in Participants With Psoriatic Arthritis in Routine Clinical Practice

NCT05049798Arthritis, Psoriatic

DrugsIL-17i·Tremfya·Guselkumab

Janssen Pharmaceutica N.V., Belgium

Observational

1,314

Bobigny, Cholet, Clermont-Ferrand, Créteil, Échirolles, Lille, Lyon, Nice

2021-08-25

Active, closed

Predictive Multimodal Signatures Associated With Response to Treatment and Prognosis of Patients With Stage IV Non-small Cell Lung Cancer

NCT04994795Non-small Cell Lung Cancer Metastatic

Sophia Genetics SAS

Observational

4,000

Bobigny, Bordeaux, Boulogne-Billancourt, Lyon, Nantes, Paris, Suresnes, Toulon

2021-08-21

Active, closed

A Phase 3 Study Evaluating Efficacy and Safety of Lanifibranor Followed by an Active Treatment Extension in Adult Patients With (NASH) and Fibrosis Stages F2 and F3 ( NATiV3 )

NCT04849728NASH - Nonalcoholic Steatohepatitis

Inventiva Pharma

Phase 3

1,000

Lyon, Strasbourg, Marseille, Dijon, Besançon, Lille, Rennes, Grenoble

2021-08-19

Recruiting

Efficacy and Safety of MB-CART2019.1 vs. SoC in Lymphoma Patients

NCT04844866Diffuse Large B-cell Lymphoma

Miltenyi Biomedicine GmbH

Phase 2

213

Créteil, Lille, Lyon, Marseille, Nantes, Pessac, Poitiers, Toulouse

2021-08-18

Recruiting

Belzutifan/MK-6482 for the Treatment of Advanced Pheochromocytoma/Paraganglioma (PPGL), Pancreatic Neuroendocrine Tumor (pNET), Von Hippel-Lindau (VHL) Disease-Associated Tumors, Advanced Gastrointestinal Stromal Tumor (wt GIST), or Solid Tumors With HIF-2α Related Genetic Alterations (MK-6482-015)

NCT04924075Pheochromocytoma/Paraganglioma, Pancreatic Neuroendocrine Tumor, Von Hippel-Lindau Disease, Advanced Gastrointestinal Stromal Tumor

DrugBelzutifan

Merck Sharp & Dohme LLC

Phase 2

355

Strasbourg, Lyon, Marseille, Le Kremlin-Bicêtre, Paris, Villejuif

2021-08-12

Active, closed

Treatment Combination of Durvalumab, Tremelimumab and Enfortumab Vedotin or Durvalumab and Enfortumab Vedotin in Patients With Muscle Invasive Bladder Cancer Ineligible to Cisplatin or Who Refuse Cisplatin

NCT04960709Muscle Invasive Bladder Cancer

DrugsEnfortumab Vedotin·Tremelimumab·Durvalumab

AstraZeneca

Phase 3

712

Amiens, Bayonne, Clermont-Ferrand, Lille, Lyon, Marseille, Montpellier, Nice

2021-08-05

Recruiting

A Study to Evaluate KIN-2787 in Participants With BRAF and/or NRAS Mutation Positive Solid Tumors

NCT04913285Solid Tumor, Adult, Non-small Cell Lung Cancer, Melanoma

Pierre Fabre Medicament

Phase 1

400

Bordeaux, Caen, Lille, Lyon, Marseille, Nantes, Nice, Paris

2021-08-04

Recruiting

Addition of Pembrolizumab to the Standard of Care Chemotherapy in Patient With SCCOHT

NCT04602377Small Cell Ovarian Carcinoma

DrugsKeytruda·Pembrolizumab

ARCAGY/ GINECO GROUP

Phase 2

Angers, Besançon, Bordeaux, Dijon, Lille, Limoges, Lyon, Montpellier

2021-08-04

Recruiting

Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC) Associated With Systemic Chemotherapy in Women With Advanced Ovarian Cancer

NCT04811703Metastatic Ovarian Carcinoma, Peritoneal Carcinomatosis, Stage III Ovarian Cancer, Stage III Fallopian Tube Cancer

Hospices Civils de Lyon

Phase 1

Lille, Lyon, Pierre-Bénite

2021-07-30

Active, closed

Sleeve Gastrectomy With Transit Bipartition(SG+TB) Versus Roux-en-Y Gastric Bypass (RYGB) for Type 3 Obesity

NCT04915014Severe Obesity

University Hospital, Lille

Not applicable

320

Lille, Lyon, Nantes, Orléans, Paris, Poitiers, Vandœuvre-lès-Nancy

2021-07-23

Recruiting

Characterization of a Functional Test for Mediterranean Family Fever Screening - 2

NCT04478409Familial Mediterranean Fever, MEFV Gene Mutation

Hospices Civils de Lyon

Observational

160

Bron, Le Chesnay, Lyon, Montpellier, Nîmes, Paris, Pierre-Bénite

2021-07-21

Recruiting

Efficacy of Regorafenib Combined With Best Supportive Care as Maintenance Treatment in High Grade Bone Sarcomas Patients

NCT04698785Bone Sarcoma, Osteosarcoma

Centre Leon Berard

Phase 2

Besançon, Bordeaux, Dijon, Lille, Lyon, Marseille, Montpellier, Nantes

2021-07-21

Active, closed

Study of LY3537982 in Cancer Patients With a Specific Genetic Mutation (KRAS G12C)

NCT04956640Carcinoma, Non-Small-Cell Lung, Colorectal Neoplasms, Endometrial Neoplasms, Ovarian Neoplasms

DrugsOlomorasib·Erbitux·Cetuximab·Pemetrexed

Eli Lilly and Company

Phase 1/2

540

Bordeaux, Lyon, Montpellier, Toulouse, Villejuif

2021-07-19

Active, closed

A Study of the Efficacy, Safety, and Pharmacokinetics of a 36-Week Refill Regimen for the Port Delivery System With Ranibizumab in Patients With Neovascular Age-Related Macular Degeneration (Velodrome)

NCT04657289Neovascular Age-related Macular Degeneration (nAMD)

DrugRanibizumab

Hoffmann-La Roche

Phase 3

451

Bordeaux, Lyon, Marseille, Paris

2021-07-14

Active, closed

Open-label Extension Trial to Evaluate the Long-term Safety of Apraglutide in Short Bowel Syndrome.

NCT05018286Short Bowel Syndrome

DrugApraglutide

VectivBio AG

Phase 3

158

Clichy, Lyon, Nantes, Nice, Pessac, Vandœuvre-lès-Nancy

2021-07-13

Active, closed

A Study of JNJ-78278343, a T-Cell-Redirecting Agent Targeting Human Kallikrein 2 (KLK2), for Advanced Prostate Cancer

NCT04898634Prostatic Neoplasms

DrugPasritamig

Janssen Research & Development, LLC

Phase 1

216

Lyon, Marseille, Villejuif

2021-07-13

Recruiting

Safety and Performance of the Hexanium TLIF System in the Treatment of Degenerative Disc Disease

NCT05997121Intervertebral Disc Degeneration

SPINEVISION SAS

Observational

187

Bruges, Lyon, Marseille, Nancy

2021-07-09

Recruiting

Liver Transplantation in Patients With CirrHosis and Severe Acute-on-Chronic Liver Failure: iNdications and outComEs

NCT04613921Liver Diseases, Liver Cirrhosis, Acute-On-Chronic Liver Failure, Liver Transplant; Complications

European Foundation for Study of Chronic Liver Failure

Observational

3,000

Clichy, Créteil, Lyon, Montpellier, Paris, Rennes, Strasbourg, Tours

2021-07-08

Recruiting

The ABC-HCC Trial: Atezolizumab Plus Bevacizumab vs. Transarterial Chemoembolization (TACE) in Intermediate-stage HepatoCellular Carcinoma

NCT04803994Hepatocellular Carcinoma

DrugsTecentriq·Avastin·Atezolizumab·Bevacizumab

Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest

Phase 3

434

Avignon, Bobigny, Bordeaux, Clermont-Ferrand, Clichy, Grenoble, Lyon, Marseille

2021-07-06

Active, closed

Beamion LUNG-1: A Study to Test Different Doses of Zongertinib in People With Different Types of Advanced Cancer (Solid Tumours With Changes in the HER2 Gene)

NCT04886804Neoplasm Metastasis, Non-Small Cell Lung Cancer

DrugZongertinib

Boehringer Ingelheim

Phase 1

554

Bron, Lyon, Marseille, Paris, Rennes, Villejuif

2021-07-02

Recruiting

Prospective Study of Immune Alterations in Operable Breast and Ovarian Carcinoma

NCT04562623Ovarian Carcinoma, Breast Carcinoma

Centre Leon Berard

Observational

160

Lyon

2021-07-01

Active, closed

Phase III Study to Assess AZD9833+ CDK4/6 Inhibitor in HR+/HER2-MBC With Detectable ESR1m Before Progression (SERENA-6)

NCT04964934ER-Positive HER2-Negative Breast Cancer

DrugsCamizestrant·Anastrozole·Ribociclib·Abemaciclib

AstraZeneca

Phase 3

315

Avignon, Brest, Clermont-Ferrand, Dijon, Limoges, Lorient, Lyon, Marseille

2021-06-30

Recruiting

Post-operative Analgesic Effect of Oral Nefopam

NCT04576078Postoperative Pain After a Total Knee Arthroplasty

DrugNefopam

Hospices Civils de Lyon

Phase 2

Lyon

2021-06-29

Active, closed

Phase 3 Study of MRTX849 With Cetuximab vs Chemotherapy in Patients With Advanced Colorectal Cancer With KRAS G12C Mutation (KRYSTAL-10)

NCT04793958Advanced Colorectal Cancer, Metastatic Colorectal Cancer

DrugsAdagrasib·MFOLFOX6·Erbitux·Folfox

Mirati Therapeutics Inc.

Phase 3

461

Chambray-lès-Tours, Avignon, Besançon, Bordeaux, Brest, Dijon, Lille, Lyon

2021-06-24

Recruiting

WE-TRUST (Workflow Optimization to Reduce Time to Endovascular Reperfusion for Ultra-fast Stroke Treatment)

NCT04701684Stroke, Acute

Philips Clinical & Medical Affairs Global

Not applicable

594

Lyon, Montpellier, Paris

2021-06-23

Active, closed

Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy for HR+/HER2- Locally Recurrent Inoperable or Metastatic Breast Cancer (MK-3475-B49/KEYNOTE-B49)

NCT04895358Breast Neoplasms

DrugsLiposomal doxorubicin·Abraxane·Xeloda·Taxol

Merck Sharp & Dohme LLC

Phase 3

342

Lyon, Marseille, Caen, Besançon, Toulouse, Montpellier, Saint-Herblain, Angers

2021-06-18

Active, closed

177Lu-PSMA-617 vs. Androgen Receptor-Directed Therapy in the Treatment of Progressive Metastatic Castrate Resistant Prostate Cancer

NCT04689828Prostatic Neoplasms

DrugsARDT·Illuccix·Lu-PSMA

Novartis Pharmaceuticals

Phase 3

469

Angers, Bordeaux, Clermont-Ferrand, Lyon, Paris, Villejuif

2021-06-15

Active, closed

An International Prospective Open-label, Randomized, Phase III Study Comparing 177Lu-PSMA-617 in Combination With Standard of Care (SoC), Versus SoC Alone, in Adult Male Patients With Metastatic Hormone Sensitive Prostate Cancer (mHSPC)

NCT04720157Prostatic Neoplasms

DrugsARDT·Illuccix·Lu-PSMA

Novartis Pharmaceuticals

Phase 3

1,140

Bordeaux, Clermont-Ferrand, Lyon, Montpellier, Nantes, Paris, Strasbourg, Vandœuvre-lès-Nancy

2021-06-09

Recruiting

PROADAPT-ovary/EWOC-2

NCT04284969Ovarian Cancer, Surgery

Hospices Civils de Lyon

Not applicable

292

Bordeaux, Chambéry, Dijon, Lyon, Pierre-Bénite, Pringy, Saint-Priest-en-Jarez, Villejuif

2021-06-03

Active, closed

Valemetostat Tosylate (DS-3201b), an Enhancer of Zeste Homolog (EZH) 1/2 Dual Inhibitor, for Relapsed/Refractory Peripheral T-Cell Lymphoma (VALENTINE-PTCL01)

NCT04703192Relapsed/Refractory Peripheral T-Cell Lymphoma, Adult T Cell Leukemia/Lymphoma

DrugValemetostat Tosylate

Daiichi Sankyo

Phase 2

155

Dijon, Lille, Lyon, Paris, Pierre-Bénite, Toulouse

2021-06-03

Recruiting

TALazoparib and Avelumab as Maintenance Therapy in Platinum-Sensitive Metastatic or Locally Advanced URothelial Carcinoma

NCT04678362Urothelial Carcinoma

DrugsTalazoparib·Avelumab

Centre Francois Baclesse

Phase 2

Angers, Besançon, Caen, Clermont-Ferrand, Dijon, Lyon, Marseille, Nantes

2021-06-01

Active, closed

Post Market Clinical Follow-up of Dual-mobility Acetabular Cup EUROSCUP MOBILE

NCT04993638Hip Arthropathy, Hip Osteoarthritis, Hip Arthritis, Hip Fractures

EUROS

Observational

147

Avignon, Clermont-Ferrand, Lyon

2021-06-01

Recruiting

HYdrocortisone and VAsopressin in Post-RESuscitation Syndrome

NCT04591990Postresuscitation Syndrome

Assistance Publique - Hôpitaux de Paris

Phase 3

380

Amiens, Angers, Aulnay-sous-Bois, Boulogne-Billancourt, Cherbourg, Dijon, Lyon, Massy

2021-05-27

Active, closed

A Clinical Study on Implants With TiUltra Technology and Associated Prosthetic Components

NCT04737421Marginal Bone Level Change

Nobel Biocare

Observational

1,000

Lyon, Montpellier, Paris

2021-05-26

Recruiting

ShOrt neCK AAA RAndomized Trial - ESAR and FEVAR: SOCRATES

NCT04503395Aortic Aneurysm, Abdominal

FCRE (Foundation for Cardiovascular Research and Education)

Not applicable

204

Boulogne, Clermont-Ferrand, Lyon, Rennes

2021-05-21

Active, closed

Value of the Laparoscopic Approach in the Surgical Management of Resectable Hepatocellular Carcinoma

NCT04791735Hepatocellular Carcinoma

Assistance Publique - Hôpitaux de Paris

Not applicable

252

Amiens, Besançon, Clichy, Créteil, Grenoble, Lille, Lyon, Montpellier

2021-05-21

Active, closed

Trastuzumab Deruxtecan for Subjects With HER2-Positive Gastric Cancer or Gastro-Esophageal Junction Adenocarcinoma After Progression on or After a Trastuzumab-Containing Regimen (DESTINY-Gastric04)

NCT04704934Gastric Cancer, Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma

DrugsRamucirumab·Trastuzumab deruxtecan·Paclitaxel

Daiichi Sankyo

Phase 3

490

Besançon, Brest, Lille, Lyon, Marseille, Montpellier, Paris, Saint-Priest-en-Jarez

2021-05-21

Active, closed

A Study of Berubicin in Adult Subjects With Recurrent Glioblastoma Multiforme

NCT04762069Glioblastoma Multiforme, Adult

DrugsCCNU·Lomustine

CNS Pharmaceuticals, Inc.

Phase 2

252

Lyon, Marseille, Montpellier, Paris, Saint-Herblain, Toulouse, Villejuif

2021-05-18

Active, closed

Study of Talazoparib With Enzalutamide in Men With DDR Gene Mutated mCSPC

NCT04821622Prostate Cancer

DrugsTalazoparib·Enzalutamide

Pfizer

Phase 3

599

Brest, Le Mans, Angers, Bayonne, Lille, Lyon, Paris, Pierre-Bénite

2021-05-12

Recruiting

Patritumab Deruxtecan (U3-1402) in Unresectable Locally Advanced or Metastatic Breast Cancer

NCT04965766Metastatic Breast Cancer, Advanced Breast Cancer

DrugPatritumab deruxtecan

Gustave Roussy, Cancer Campus, Grand Paris

Phase 2

139

Dijon, Limoges, Lyon, Marseille, Montpellier, Nice, Paris, Saint-Herblain

2021-05-11

Active, closed

3 Month Study of Alocross Versus Vismed in Adults With Dry Eye Disease Related to Keratitis or Keratoconjunctivitis

NCT04685109Dry Eye Syndromes

Santen SAS

Not applicable

Brest, La Rochefoucauld, Lyon, Nantes, Paris, Le Kremlin-Bicêtre

2021-05-11

Active, closed

Capivasertib + CDK4/6i + Fulvestrant for Advanced/Metastatic HR+/HER2- Breast Cancer (CAPItello-292)

NCT04862663Locally Advanced (Inoperable) or Metastatic Breast Cancer

DrugsCapivasertib·Ribociclib·Abemaciclib·Palbociclib

AstraZeneca

Phase 3

893

Bobigny, Limoges, Lyon, Plérin, Rouen, Saint-Herblain, Villejuif

2021-05-10

Recruiting

Impact of Telemonitoring for the Management of Side Effects in Patients with Melanoma, Lung or Renal Cancer, Treated with Immunotherapy Combination of Nivolumab and Ipilimumab or Adjuvant Nivolumab Monotherapy

NCT04605146Melanoma, Lung Cancer, Renal Cancer

Hospices Civils de Lyon

Not applicable

100

Bron, Grenoble, Lyon, Pierre-Bénite, Saint-Etienne

2021-05-05

Active, closed

Real World Study of the Tendyne™ Mitral Valve System to Treat Mitral Regurgitation

NCT04818502Mitral Valve Regurgitation

Abbott Medical Devices

Observational

200

Bordeaux, Lille, Lyon, Rennes, Toulouse

2021-05-04

Active, closed

A Study Evaluating the Efficacy and Safety of Adjuvant Atezolizumab or Placebo and Trastuzumab Emtansine for Participants With HER2-Positive Breast Cancer at High Risk of Recurrence Following Preoperative Therapy

NCT04873362Breast Cancer

DrugsTrastuzumab emtansine·Herceptin·Tecentriq·Trastuzumab

Hoffmann-La Roche

Phase 3

1,188

Avignon, Besançon, Bordeaux, Brest, Caen, Creil, Lyon, Nîmes

2021-05-04

Recruiting

Diagnostic Yield of Post PRandial Esophageal High Resolution Impedance Manometry in Patients With Gastro-Esophageal Reflux Disease Symptoms Resistant to Proton Pump Inhibitor Therapy

NCT03596476Gastro-esophageal Reflux Disease

Hospices Civils de Lyon

Not applicable

330

Chambray-lès-Tours, Colombes, Lyon, Nantes, Pessac, Rennes, Rouen

2021-05-03

Active, closed

A Study of Atezolizumab Versus Placebo as Adjuvant Therapy in Participants With High-risk Muscle-invasive Bladder Cancer (MIBC) Who Are ctDNA Positive Following Cystectomy

NCT04660344Muscle-invasive Bladder Cancer

DrugsTecentriq·Atezolizumab

Hoffmann-La Roche

Phase 3

761

Angers, Avignon, Bordeaux, Clermont-Ferrand, Lyon, Nancy, Paris, Suresnes

2021-05-03

Recruiting

Multimodal Immune Characterization of RAre Soft Tissue Sarcoma - MIRAS Project From SARRA (SARcome RAre) Project of the French Sarcoma Group

NCT03967834Soft Tissue Sarcoma, Clear Cell Sarcoma, Epithelioid Sarcoma, Perivascular Epithelioid Cell Neoplasms

Institut Claudius Regaud

Not applicable

400

Besançon, Bordeaux, Clermont-Ferrand, Dijon, Lille, Limoges, Lyon, Marseille

2021-04-26

Recruiting

RESTORE - Study of AGN1 LOEP to Prevent Secondary Hip Fractures

NCT04796350Fragility Fracture, Hip Fractures, Osteoporosis

AgNovos Healthcare, LLC

Not applicable

2,400

Nice, Amiens, Grenoble, Lyon, Toulouse

2021-04-24

Recruiting

LEGEND Study: EG-70 in NMIBC Patients BCG-Unresponsive and High-Risk NMIBC Incompletely Treated With BCG or BCG-Naïve

NCT04752722Superficial Bladder Cancer, Non-muscle Invasive Bladder Cancer With Carcinoma in Situ, Non-muscle Invasive Bladder Cancer

DrugPhase 2

enGene, Inc.

Phase 1/2

350

Angers, Bordeaux, Lille, Lyon, Paris, Rouen

2021-04-22

Active, closed

Optimization of the Parameters of Vagal Nerve Stimulation

NCT04693221Epilepsy

Assistance Publique Hopitaux De Marseille

Not applicable

140

Amiens, Angers, Bordeaux, Dijon, Grenoble, Lille, Lyon, Marseille

2021-04-16

Active, closed

A Study to Assess the Safety and Efficacy of IPN10200 in Adult Participants With Moderate to Severe Upper Facial Lines

NCT04821089Moderate to Severe Upper Facial Lines

DrugsDysport·Corabotase

Ipsen

Phase 1/2

727

Antibes, Lyon, Paris

2021-04-06

Recruiting

Study of Sacituzumab Govitecan in Participants With Advanced or Metastatic Solid Tumor and Moderate Liver Impairment

NCT04617522Advanced or Metastatic Solid Tumor, Liver Failure

DrugSacituzumab Govitecan

Gilead Sciences

Phase 1

Bordeaux, Lyon, Saint-Herblain

2021-04-06

Active, closed

Research Study on Whether Semaglutide Works in People With Non-alcoholic Steatohepatitis (NASH)

NCT04822181Non-alcoholic Steatohepatitis

DrugSemaglutide

Novo Nordisk A/S

Phase 3

1,205

Angers, Clichy, Lille, Lyon, Nice, Paris, Pessac, Pierre-Bénite

2021-04-01

Recruiting

Circulating Tumor DNA in Primary Mediastinal Large B-cell Lymphoma (PMBL)

NCT04824950Primary Mediastinal Large B-cell Lymphoma

Centre Henri Becquerel

Not applicable

Lyon, Rouen

2021-03-22

Active, closed

ENdoluminal LIGHT ActivatED Treatment of Upper Tract Urothelial Cancer (ENLIGHTED) Study

NCT04620239Transitional Cell Cancer of Renal Pelvis and Ureter

Steba Biotech S.A.

Phase 3

Lille, Lyon

2021-03-22

Active, closed

A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase III Study of Fuzuloparib Combined With Abiraterone Acetate and Prednisone (AA-P) Versus Placebo Combined With AA-P as First-Line Treatment in Patients With Metastatic Castration-Resistant Prostate Cancer

NCT04691804Metastatic Castration-Resistant Prostate Cancer (mCRPC)

DrugFluzoparib

Jiangsu HengRui Medicine Co., Ltd.

Phase 3

496

La Roche-sur-Yon, Lille, Lyon, Nîmes, Paris, Pierre-Bénite, Rennes, Saint-Herblain

2021-03-18

Active, closed

A Study of Teclistamab With Other Anticancer Therapies in Participants With Multiple Myeloma

NCT04722146Multiple Myeloma

DrugsNirogacestat·Teclistamab·Pomalidomide·Bortezomib

Janssen Research & Development, LLC

Phase 1

140

Lyon, Nantes, Pessac, Rennes, Toulouse

2021-03-12

Recruiting

Creation of a Register of Patients With Neonatal-onset Epileptic Encephalopathy

NCT04802135Epileptic Encephalopathy

Assistance Publique Hopitaux De Marseille

Observational

200

Angers, Bordeaux, Brest, Lille, Limoges, Lyon, Marseille, Montpellier

2021-03-06

Recruiting

Efficacy of Dorso-lateral Prefrontal Cortex Stimulation by tDCS in Motor Conversion Disorder Patients

NCT04097184Conversion Disorder

Centre Hospitalier Universitaire de Nīmes

Not applicable

Nîmes, Montpellier, Lyon, Nantes, Toulouse, Paris

2021-03-05

Active, closed

An Efficacy and Safety Study of Luspatercept (ACE-536) Versus Placebo in Subjects With Myeloproliferative Neoplasm-Associated Myelofibrosis on Concomitant JAK2 Inhibitor Therapy and Who Require Red Blood Cell Transfusions

NCT04717414Myeloproliferative Disorders, Myelofibrosis, Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis

DrugLuspatercept

Celgene

Phase 3

313

Angers, Clermont-Ferrand, Créteil, Grenoble, Lille, Lyon, Nice, Nîmes

2021-02-25

Active, closed

Study Evaluating mCRPC Treatment Using PSMA [Lu-177]-PNT2002 Therapy After Second-line Hormonal Treatment

NCT04647526Metastatic Castration-Resistant Prostate Cancer

DrugsAbiraterone·Enzalutamide

POINT Biopharma, a wholly owned subsidiary of Eli Lilly and Company

Phase 3

455

Clermont-Ferrand, Lille, Lyon, Marseille, Montpellier, Paris

2021-02-25

Active, closed

Study of JDQ443 in Patients With Advanced Solid Tumors Harboring the KRAS G12C Mutation

NCT04699188KRAS G12C Mutant Solid Tumors, Carcinoma, Non-Small-Cell Lung, Carcinoma, Colorectal, Cancer of Lung

DrugsTNO155·Opnurasib·Tislelizumab

Novartis Pharmaceuticals

Phase 1/2

344

Lyon, Marseille, Villejuif

2021-02-24

Active, closed

Phase 3 Study of MRTX849 (Adagrasib) vs Docetaxel in Patients With Advanced Non-Small Cell Lung Cancer With KRAS G12C Mutation

NCT04685135Metastatic Non Small Cell Lung Cancer, Advanced Non Small Cell Lung Cancer

DrugsAdagrasib·Taxotere·Docetaxel

Mirati Therapeutics Inc.

Phase 3

453

Pierre-Bénite, Lyon, Brest, Bron, Caen, Créteil, Dijon, Gleizé

2021-02-23

Recruiting

An Observational Post-marketing Study Using Commercially Approved Biosense Webster (BWI) Medical Devices for the Treatment of Participants With Cardiac Arrhythmias

NCT04750798Arrhythmias, Cardiac

Biosense Webster, Inc.

Observational

8,000

Clermont-Ferrand, Lyon, Marseille, Paris, Rennes, Strasbourg, Talence

2021-02-22

Active, closed

European TauroPace Registry - University of Schleswig-Holstein Prospective Observational Clinical Study

NCT04735666CIED Related Infection

University of Kiel

Observational

2,300

Lyon

2021-02-22

Active, closed

HERTHENA-Lung01: Patritumab Deruxtecan in Subjects With Metastatic or Locally Advanced EGFR-mutated Non-Small Cell Lung Cancer

NCT04619004Non-Small Cell Lung Cancer Metastatic, Non-Small Cell Lung Cancer With Mutation in Epidermal Growth Factor Receptor

DrugPatritumab deruxtecan

Daiichi Sankyo

Phase 2

277

Toulouse, Nantes, Lyon, Brest, Grenoble, Paris, Rennes, Villejuif

2021-02-02

Recruiting

A Study of Talquetamab in Participants With Relapsed or Refractory Multiple Myeloma

NCT04634552Hematological Malignancies

DrugTalquetamab

Janssen Research & Development, LLC

Phase 2

510

Créteil, Lyon, Montpellier, Nantes, Pessac, Toulouse

2021-02-01

Recruiting

Annuloplasty Rings and Band Post-Market Clinical Follow-Up Study

NCT04761120Mitral Regurgitation, Tricuspid Regurgitation, Valvular Heart Disease

Abbott Medical Devices

Observational

550

Lyon, Besançon

2021-02-01

Recruiting

SCAD : a Registry of Spontaneous Coronary Artery Dissection

NCT06601270Spontaneous Coronary Artery Dissection

European Society of Cardiology

Observational

1,500

Besançon, Clermont-Ferrand, Le Coudray, Lyon, Massy, Pessac

2021-01-30

Active, closed

A Study of Etavopivat in Adults and Adolescents With Sickle Cell Disease (HIBISCUS)

NCT04624659Sickle Cell Disease

DrugEtavopivat

Forma Therapeutics, Inc.

Phase 3

450

Créteil, Lyon, Montpellier, Mulhouse, Paris, Saint-Denis

2021-01-29

Recruiting

Surgery With or Without Neoadjuvant Chemotherapy in High Risk RetroPeritoneal Sarcoma

NCT04031677Retroperitoneal Sarcoma, Liposarcoma, Leiomyosarcoma

European Organisation for Research and Treatment of Cancer - EORTC

Phase 3

250

Lyon, Montpellier, Paris, Strasbourg, Villejuif

2021-01-20

Active, closed

Tumor-agnostic Precision Immuno-oncology and Somatic Targeting Rational for You (TAPISTRY) Platform Study

NCT04589845Solid Tumors

DrugsCamonsertib·Belvarafenib·Pralsetinib·Divarasib

Hoffmann-La Roche

Phase 2

920

Bordeaux, Lille, Lyon, Marseille, Toulouse, Villejuif

2021-01-18

Active, closed

A Phase 3 Trial of Epcoritamab vs Investigator's Choice Chemotherapy in Relapsed/Refractory (R/R) Diffuse Large B-cell Lymphoma (DLBCL)

NCT04628494Diffuse Large B-cell Lymphoma

DrugEpcoritamab

Genmab

Phase 3

483

Amiens, Bayonne, Brest, Caen, La Rochelle, Limoges, Lyon, Marseille

2021-01-13

Recruiting

Efficacy of Neoadjuvant Chemotherapy in Terms of DFS in Patients With Localized Digestive Neuroendocrine Carcinomas

NCT04268121Neuroendocrine Carcinoma, Digestive Cancer

GERCOR - Multidisciplinary Oncology Cooperative Group

Phase 2

Amiens, Besançon, Clichy, Dijon, Lyon, Marseille, Paris, Pessac

2021-01-05

Active, closed

A Study of T-DXd for the Treatment of Solid Tumors Harboring HER2 Activating Mutations

NCT04639219Advanced Solid Tumors With HER2 Mutation,eg:Colorectal,Urothelial,Gastric, Hepatobiliary,Endometrial,Melanoma,Ovarian,Cervical,Salivary Gland,Pancreatic,Breast

DrugTrastuzumab deruxtecan

AstraZeneca

Phase 2

102

Bordeaux, Lyon, Villejuif

2020-12-30

Active, closed

A Post-treatment Program to Identify and Manage Complications Related to Oncology or Hematology Treatments in Cancer Survivors.

NCT04671693Late Effects, Testicular Germ Cell Tumor Mixed, Non-Metastatic Breast Carcinoma, Soft Tissue Sarcoma, Adult, Stage IIC

Centre Leon Berard

Not applicable

500

Lyon

2020-12-24

Active, closed

Study of DS-1062a Versus Docetaxel in Previously Treated Advanced or Metastatic Non-small Cell Lung Cancer With or Without Actionable Genomic Alterations (TROPION-LUNG01)

NCT04656652Non-small Cell Lung Cancer

DrugsDato-DXd·Docetaxel

Daiichi Sankyo

Phase 3

605

Besançon, Grenoble, Lyon, Marseille, Nantes, Paris, Poitiers, Rennes

2020-12-21

Active, closed

A Trial to Find Out How Safe REGN7075 is and How Well it Works in Combination With Cemiplimab for Adult Participants With Advanced Cancers

NCT04626635Advanced Solid Tumors

DrugsMarlotamig·Trifluridine/Tipiracil·Cemiplimab·Bevacizumab

Regeneron Pharmaceuticals

Phase 1/2

548

Lyon, Pierre-Bénite, Dijon, Toulouse, Lille, Bordeaux, Poitiers, Nantes

2020-12-21

Active, closed

A Study of Avutometinib (VS-6766) v. Avutometinib (VS-6766) + Defactinib in Recurrent Low-Grade Serous Ovarian Cancer With and Without a KRAS Mutation

NCT04625270Low Grade Ovarian Serous Adenocarcinoma, Ovarian Cancer

DrugsAvutometinib (VS-6766) and defactinib·Avutometinib·Sotorasib

Verastem, Inc.

Phase 2

225

Besançon, Lyon, Montpellier, Paris

2020-12-21

Active, closed

A Study of TAR-200 in Combination With Cetrelimab, TAR-200 Alone, or Cetrelimab Alone in Participants With Non-Muscle Invasive Bladder Cancer (NMIBC) Unresponsive to Intravesical Bacillus Calmette-Guérin Who Are Ineligible for or Elected Not to Undergo Radical Cystectomy

NCT04640623Urinary Bladder Neoplasms

DrugsTAR-200·Cetrelimab

Janssen Research & Development, LLC

Phase 2

220

Bordeaux, Grenoble, Hyères, Limoges, Lyon, Marseille, Montpellier, Nîmes

2020-12-18

Active, closed

GYNecological Cancers Treated with NETrin MAbs in Combination with Chemotherapy and /or Pembrolizumab

NCT04652076Endometrial Carcinoma, Cervix Carcinoma

DrugsNP137·Keytruda·Paclitaxel·Carboplatin

NETRIS Pharma

Phase 1/2

240

Besançon, Bordeaux, Caen, Dijon, Lille, Lyon, Marseille, Montpellier

2020-12-14

Recruiting

Predictive Toxicity Test Linked to Radiotherapy After Mastectomy and Immediate Implant Reconstruction

NCT04342546Breast Cancer, Capsular Contracture Associated With Breast Implant

Institut du Cancer de Montpellier - Val d'Aurelle

Not applicable

250

Dijon, Lille, Lyon, Marseille, Montpellier, Nice, Paris, Saint-Herblain

2020-12-11

Active, closed

A Study of TAR-200 in Combination With Cetrelimab Versus Concurrent Chemoradiotherapy in Participants With Muscle-invasive Bladder Cancer (MIBC) of the Bladder

NCT04658862Urinary Bladder Neoplasms

DrugsTAR-200·Cetrelimab·Gemcitabine·Cisplatin

Janssen Research & Development, LLC

Phase 3

518

Bordeaux, Brest, Caen, Chambray-lès-Tours, Hyères, Lille, Limoges, Lyon

2020-12-07

Recruiting

Ovarian Reserve and Bariatric Surgery

NCT04583150Bariatric Surgery, Obesity, Reproductive Health, Fertility

Assistance Publique - Hôpitaux de Paris

Observational

238

Angers, Clermont-Ferrand, Colombes, Dijon, Grenoble, Lille, Lyon, Marseille

2020-12-03

Recruiting

Efficiency of Everolimus for the Treatment of Kidney Transplanted Patients Presenting a Missing Self-induced NK-mediated Rejection

NCT03955172Kidney Transplant Failure and Rejection

DrugEverolimus

Hospices Civils de Lyon

Not applicable

Lyon

2020-12-03

Active, closed

Restoration of Central Vision With the PRIMA System in Patients With Atrophic AMD

NCT04676854Geographic Atrophy

Science Corporation

Not applicable

Lyon, Bordeaux, Créteil, Marseille, Nantes, Paris

2020-11-24

Active, closed

Assessing Durvalumab and FLOT Chemotherapy in Resectable Gastric and Gastroesophageal Junction Cancer

NCT04592913Gastrointestinal Neoplasms, Esophagogastric Junction

DrugDurvalumab

AstraZeneca

Phase 3

957

Avignon, Besançon, Brest, Dijon, Lyon, Montpellier, Nantes, Nice

2020-11-17

Active, closed

Relapse in Previously Irradiated Prostate Bed : Stereotactic Ablative Reirradiation Potentiated by Metformin

NCT04536805Prostate Cancer

DrugMetformin

Institut Cancerologie de l'Ouest

Phase 1/2

Angers, Brest, Chambray-lès-Tours, Dijon, Le Mans, Lille, Lyon, Rennes

2020-11-17

Recruiting

Cultured Autologous Oral Mucosa Epithelial Sheet for the Treatment of Bilateral Limbal Stem Cell Deficiency

NCT03949881Total Bilateral Limbal Cell Deficiency

Hospices Civils de Lyon

Phase 1/2

Lyon

2020-11-13

Recruiting

Understanding of Psychotic Disorders in Children With 22q11.2DS

NCT0463938822q11.2 Deletion Syndrome

Hôpital le Vinatier

Not applicable

Lyon

2020-11-13

Recruiting

Hematological Anomalies in Children With Rasopathy

NCT04286360RAS Mutation

Assistance Publique - Hôpitaux de Paris

Observational

300

Angers, Caen, Lille, Lyon, Marseille, Montpellier, Nantes, Paris

2020-11-11

Active, closed

Exhaled Breath Analysis Using eNose Technology as a Biomarker for Diagnosis and Disease Progression in Fibrotic ILD

NCT04680832Pulmonary Fibrosis

Erasmus Medical Center

Observational

600

Lyon

2020-11-01

Recruiting

CHoice of OptImal transCatheter trEatment for Mitral Insufficiency Registry

NCT04688190Mitral Regurgitation, Mitral Valve Disease, Mitral Annular Calcification

Universitätsklinikum Hamburg-Eppendorf

Observational

1,000

Bourdeaux, Lille, Lyon, Toulouse

2020-11-01

Recruiting

The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)

NCT04585750Advanced Solid Tumor, Advanced Malignant Neoplasm, Metastatic Cancer, Metastatic Solid Tumor

DrugsRezatapopt·Keytruda·Pembrolizumab

PMV Pharmaceuticals, Inc

Phase 1/2

300

Strasbourg, Bordeaux, Toulouse, Saint-Herblain, Clermont-Ferrand, Villejuif, Lyon, Nîmes

2020-10-29

Recruiting

The AFteR Registry - Follow-up Study to Monitor the Efficacy and Safety of the Occlutech AFR in Heart Failure Patients

NCT04405583Heart Failure

Occlutech International AB

Observational

150

Besançon, Bourdeaux, Lyon, Montpellier, Toulouse

2020-10-28

Active, closed

Study of Durvalumab Versus Placebo in Combination With Definitive Chemoradiation Therapy in Patient With ESCC

NCT04550260Esophageal Squamous Cell Carcinoma

DrugsFluorouracil·Durvalumab·Capecitabine·Cisplatin

AstraZeneca

Phase 3

640

Besançon, Lille, Lyon, Montpellier, Reims, Rouen, Strasbourg, Villejuif

2020-10-19

Recruiting

Interest of Peri Operative CHemotherapy In Patients With CINSARC High-risk Localized Soft Tissue Sarcoma

NCT04307277Soft Tissue Sarcoma

Institut Claudius Regaud

Phase 3

600

Besançon, Caen, Clermont-Ferrand, Dijon, Limoges, Lyon, Marseille, Montpellier

2020-10-09

Active, closed

Microbial Biomarkers of EArly Pseudomonas Aeruginosa Colonization in CHildren With Cystic Fibrosis

NCT03947957Cystic Fibrosis

University Hospital, Brest

Not applicable

Angers, Bordeaux, Grenoble, Lyon, Nantes, Paris, Rennes, Roscoff

2020-10-02

Active, closed

Assessment of Efficacy and Safety of Monalizumab Plus Cetuximab Compared to Placebo Plus Cetuximab in Recurrent or Metastatic Head and Neck Cancer

NCT04590963Squamous Cell Carcinoma of the Head and Neck

DrugsMonalizumab·Erbitux·Cetuximab

AstraZeneca

Phase 3

370

Avignon, Bordeaux, Clermont-Ferrand, Dijon, Lyon, Marseille, Montpellier, Strasbourg

2020-10-02

Active, closed

Optimal Timing of Transcatheter Aortic Valve Implantation and Percutaneous Coronary Intervention - The TAVI PCI Trial

NCT04310046Aortic Stenosis, Coronary Artery Disease, TAVI, PCI

University of Zurich

Not applicable

986

Dijon, Lyon, Marseille, Nice, Toulouse

2020-09-30

Active, closed

A Study of Niraparib in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for the Treatment of Participants With Deleterious Germline or Somatic Homologous Recombination Repair (HRR) Gene-MutatedProstatic Neoplasms (mCSPC)

NCT04497844Prostatic Neoplasms

DrugsAbiraterone acetate·Prednisone

Janssen Research & Development, LLC

Phase 3

696

Angers, Avignon, Besançon, Bordeaux, Clermont-Ferrand, Dijon, Lille, Lyon

2020-09-23

Active, closed

A Study of Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma

NCT04557098Hematological Malignancies

DrugTeclistamab

Janssen Research & Development, LLC

Phase 2

194

Lille, Lyon, Nantes, Poitiers, Toulouse, Tours

2020-09-17

Active, closed

PREdiction of Chronic LUng Allograft Dysfunction

NCT03967340Lung Transplant Rejection

Nantes University Hospital

Observational

240

Bordeaux, Grenoble, Le Plessis-Robinson, Lyon, Marseille, Nantes, Paris, Strasbourg

2020-09-10

Recruiting

Predictive Factors of Autonomy Loss in Real-life Cohort

NCT03894254Memory Disorders

Hospices Civils de Lyon

Not applicable

5,400

Caluire-et-Cuire, Lyon, Saint-Etienne, Villeurbanne

2020-09-09

Recruiting

Evaluation of Walking Analysis After a Total Knee Arthroplasty With Kinematic Alignment Versus Mechanical Alignment

NCT04226339Knee Arthroplasty, Total

Hospices Civils de Lyon

Not applicable

104

Lyon

2020-09-07

Active, closed

A Phase 1 Trial of ZN-A-1041 Enteric Capsules or Combination in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Advanced Solid Tumors

NCT05593094Advanced Solid Tumors, HER2-positive Breast Cancer

DrugZN-A-1041

Hoffmann-La Roche

Phase 1/2

210

Toulouse, Dijon, Lille, Lyon, Marseille, Saint-Herblain, Villejuif

2020-09-03

Recruiting

PITCHER (Peritoneal Carcinomatosis Heterogeneity)

NCT04714957Secondary Peritoneal Cancers, Colorectal Cancer, Ovarian Cancer

Hospices Civils de Lyon

Observational

Lyon

2020-09-01

Recruiting

PATAKESS Protocol : Clinical and Biological Analysis of Exocrine Pancreatic Tumors

NCT04011982Exocrine Pancreatic Cancer

Centre Leon Berard

Observational

300

Lyon

2020-09-01

Active, closed

Efficacy and Safety of L19TNF in Previously Treated Patients with Advanced Stage or Metastatic Soft-tissue Sarcoma

NCT04733183Soft Tissue Sarcoma

DrugsOnfekafusp alfa·Dacarbazine

Philogen S.p.A.

Phase 2

Besançon, Bordeaux, Clermont-Ferrand, Lyon, Marseille, Montpellier, Toulouse, Villejuif

2020-08-28

Active, closed

MINIject Global Long-Term Follow-up Study

NCT04524416Open Angle Glaucoma, Ocular Hypertension

iSTAR Medical

Observational

116

Grenoble, Lyon

2020-08-05

Active, closed

Roll Over StudY for Patients Who Have Completed a Previous Oncology Study With Olaparib

NCT04421963Ovarian Cancer, Breast Cancer

DrugOlaparib

AstraZeneca

Phase 3

185

Lille, Lyon, Plérin, Villejuif

2020-08-04

Recruiting

Lyon Registry of Stroke Treated by Thrombolysis or Thrombectomy

NCT04620642Ischemic Stroke

Hospices Civils de Lyon

Observational

4,500

Lyon

2020-08-01

Active, closed

Study BT8009-100 in Subjects With Nectin-4 Expressing Advanced Malignancies

NCT04561362Urinary Bladder Neoplasm, Triple Negative Breast Neoplasms, Hormone Receptor Positive, HER2-negative Neoplasms, Hormone Receptor Positive, HER2-low Neoplasms

DrugsZelenectide pevedotin·Keytruda·Pembrolizumab

BicycleTx Limited

Phase 1/2

329

Bordeaux, Lyon, Marseille, Rennes, Villejuif

2020-07-17

Recruiting

OP2C : Prialt® Observatory in Clinical Practice

NCT04321408Refractory Pain

DrugZiconotide

Institut Cancerologie de l'Ouest

Observational

300

Angers, La Roche-sur-Yon, Lyon, Montpellier, Nantes, Nice, Saint-Cloud, Suresnes

2020-07-10

Active, closed

Bosutinib in Pediatric Patients With Newly Diagnosed Chronic Phase or Resistant/Intolerant Ph + Chronic Myeloid Leukemia

NCT04258943Philadelphia Chromosome Positive CML, Accelerated Phase Chronic Myelogenous Leukemia, Blastic Phase Chronic Myelogenous Leukemia, Chronic Phase Chronic Myelogenous Leukemia

DrugBosutinib

Children's Oncology Group

Phase 1/2

Lyon, Paris

2020-07-06

Recruiting

VACcination of LIver Transplantation Candidates

NCT04446832Liver Transplant; Complications, Vaccination; Complications, Cirrhosis, Chronic Hepatitis

Hospices Civils de Lyon

Observational

100

Lyon

2020-07-06

Recruiting

A Computer-based Cognitive Remediation Program for Adults With Intellectual Disability

NCT04025398Intellectual Disability

Hôpital le Vinatier

Not applicable

116

Lyon

2020-06-17

Active, closed

A Study Comparing JNJ-68284528, a CAR-T Therapy Directed Against B-cell Maturation Antigen (BCMA), Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) or Daratumumab, Pomalidomide and Dexamethasone (DPd) in Participants With Relapsed and Lenalidomide-Refractory Multiple Myeloma

NCT04181827Multiple Myeloma

DrugsCilta-cel·Pomalidomide·Bortezomib·Daratumumab

Janssen Research & Development, LLC

Phase 3

419

Lille, Lyon, Montpellier, Nantes, Paris, Poitiers, Toulouse

2020-06-12

Active, closed

A Study of LY3295668 Erbumine in Participants With Relapsed/Refractory Neuroblastoma

NCT04106219Neuroblastoma

DrugsTopotecan·Cyclophosphamide

Eli Lilly and Company

Phase 1

Lyon, Paris

2020-06-11

Recruiting

Stereotaxic Body Irradiation of Oligometastase in Sarcoma (Stereosarc)

NCT03548428Sarcoma, Radiosurgery

DrugAtezolizumab

Centre Antoine Lacassagne

Phase 2

103

Bordeaux, Caen, Dijon, Lille, Lyon, Marseille, Montpellier, Nice

2020-06-04

Recruiting

Clinical Surveillance vs. Anticoagulation for Low-risk Patients With Isolated Subsegmental Pulmonary Embolism

NCT04263038Pulmonary Embolism, Embolism, Embolism and Thrombosis, Lung Diseases

DrugRivaroxaban

Drahomir Aujesky

Phase 4

276

Le Kremlin-Bicêtre, Brest, Clermont-Ferrand, Dijon, Lyon, Marseille, Rouen, Saint-Priest-en-Jarez

2020-05-15

Recruiting

COVID-19 - Study of the Kinetics of the Immune Response During the Intensive Care Unit Stay in Adult Patients Infected With SARS-CoV-2: Multicentric Non Interventional Study

NCT04392401Intensive Care Unit, SARS-Cov-2

Hospices Civils de Lyon

Observational

200

Bron, Clermont-Ferrand, Grenoble, Lyon, Pierre-Bénite, Saint-Etienne

2020-05-11

Recruiting

EORTC Metastatic Breast Cancer Module Development

NCT07806266Metastatic Beast Cancer

University of Leeds

Observational

568

Lyon, Nîmes, Saint-Etienne

2020-05-01

Active, closed

Enfortumab Vedotin and Pembrolizumab vs. Chemotherapy Alone in Untreated Locally Advanced or Metastatic Urothelial Cancer

NCT04223856Urothelial Cancer

DrugsEnfortumab Vedotin·Keytruda·Gemcitabine·Cisplatin

Astellas Pharma Global Development, Inc.

Phase 3

886

Bordeaux, Lyon, Nice, Pierre-Bénite, Strasbourg, Tours, Villejuif-Cedex-France

2020-03-30

Active, closed

the Prophylaxis of Recurrent Pouchitis After Fecal Microbiota Transplant in UC With Ileo-anal Anastomosis

NCT03524352Pouchitis

Nantes University Hospital

Phase 3

Angers, Clermont-Ferrand, Clichy, Créteil, Lille, Lyon, Nancy, Nantes

2020-03-12

Recruiting

A Study of Repotrectinib in Pediatric and Young Adult Subjects Harboring ALK, ROS1, OR NTRK1-3 Alterations

NCT04094610Locally Advanced Solid Tumors, Metastatic Solid Tumors, Lymphoma, Primary CNS Tumors

DrugRepotrectinib

Turning Point Therapeutics, Inc.

Phase 1/2

Lyon, Angers, Bordeaux, Marseille, Nantes, Paris, Villejuif

2020-03-12

Active, closed

First-in-Human Study of ICT01 in Patients With Advanced Cancer

NCT04243499Solid Tumor, Adult, Hematopoietic/Lymphoid Cancer

ImCheck Therapeutics, an Ipsen company

Phase 1/2

293

Bordeaux, Lyon, Marseille, Nantes, Nice, Paris, Poitiers

2020-03-05

Recruiting

Efficacy and Safety of Regorafenib as Maintenance Therapy After First-line Treatment in Patients With Bone Sarcomas

NCT04055220Bone Sarcoma, Osteosarcoma, Ewing Sarcoma, Chondrosarcoma

DrugRegorafenib

Centre Leon Berard

Not applicable

168

Besançon, Bordeaux, Lille, Lyon, Marseille, Montpellier, Paris, Poitiers

2020-03-03

Active, closed

Safety and Efficacy of IMC-F106C as a Single Agent and in Combination With Checkpoint Inhibitors

NCT04262466Select Advanced Solid Tumors

DrugBrenetafusp

Immunocore Ltd

Phase 1/2

410

Bordeaux, Villejuif, Lyon, Paris

2020-02-25

Active, closed

Monitoring to the Evolution of Motor Function in SMA Type II Adults Patients Treated With SPINRAZA®

NCT04159987Spinal Muscular Atrophy

Centre Hospitalier Universitaire de Nice

Not applicable

Lyon, Lille, Montpellier, Toulouse, Marseille, Nice, Paris

2020-02-25

Active, closed

A Study of Selpercatinib (LY3527723) in Participants With Advanced or Metastatic RET Fusion-Positive Non-Small Cell Lung Cancer

NCT04194944Non-Small Cell Lung Cancer

DrugsSelpercatinib·Pemetrexed·Cisplatin·Carboplatin

Eli Lilly and Company

Phase 3

261

Lyon, Marseille, Montpellier, La Tronche, Clermont-Ferrand, Paris

2020-02-17

Active, closed

A Study of Selpercatinib (LY3527723) in Participants With RET-Mutant Medullary Thyroid Cancer

NCT04211337Medullary Thyroid Cancer

DrugsVandetanib·Selpercatinib·Cabozantinib

Loxo Oncology, Inc.

Phase 3

291

Strasbourg, Bordeaux, Lyon, Marseille, Caen, Dijon, Toulouse, Angers

2020-02-11

Active, closed

Study Evaluating the Efficacy of a Double Immunotherapy Combined With Olaparib in Patients With Solid Cancers and Carriers of Homologous Recombination Repair Genes After Olaparib Treatment

NCT04169841Immunotherapy

Centre Georges Francois Leclerc

Phase 2

270

Amiens, Besançon, Bordeaux, Dijon, Levallois-Perret, Lille, Lyon

2020-02-10

Recruiting

Pilot Study: Interest of Belatacept as a Non-nephrotoxic Immunosuppressive Treatment in Cardiac Transplant Patients at Risk of Chronic Renal Failure (BELACOEUR)

NCT04180085Heart Transplant Failure

DrugBelatacept

Nantes University Hospital

Phase 2

Bordeaux, Lyon, Nantes, Rennes

2020-02-06

Active, closed

A Study Evaluating the Efficacy and Safety of Inavolisib + Palbociclib + Fulvestrant vs Placebo + Palbociclib + Fulvestrant in Participants With PIK3CA-Mutant, Hormone Receptor-Positive, HER2-Negative, Locally Advanced or Metastatic Breast Cancer

NCT04191499Breast Cancer

DrugsInavolisib·Palbociclib·Fulvestrant

Hoffmann-La Roche

Phase 2/3

325

Clermont-Ferrand, Dijon, Lille, Lyon, Toulouse

2020-01-29

Recruiting

A Study Evaluating the Activity of Anti-cancer Treatments Targeting Tumor Molecular Alterations/Characteristics in Advanced / Metastatic Tumors.

NCT04116541Malignant Solid Tumor

DrugsSiremadlin·Avapritinib·Alectinib·Dabrafenib

Centre Leon Berard

Phase 2

455

Angers, Bordeaux, Caen, Lyon, Marseille, Nice, Paris, Rouen

2020-01-28

Recruiting

A Master Protocol (LY900023) That Includes Several Clinical Trials of Drugs for Children and Young Adults With Cancer

NCT05999994Neoplasms, Child, Adolescent

DrugsRamucirumab·Vinorelbine·Abemaciclib·Temozolomide

Eli Lilly and Company

Phase 2

105

Bordeaux, Lyon, Paris

2020-01-22

Recruiting

Impact of Mindfulness Intervention on Quality of Life in Patients With Drug-resistant Epilepsy.

NCT04126369Drug Resistant Epilepsy

University Hospital, Grenoble

Not applicable

100

Grenoble, Lyon, Tain-l'Hermitage

2020-01-20

Recruiting

Constitution of a Biobank for Studies Related to Organ Transplantation (Lyon Centaure Biocollection)

NCT04687865Organ Transplantation

Hospices Civils de Lyon

Observational

4,000

Lyon

2020-01-08

Active, closed

Study to Evaluate the Efficacy and Safety of Lutathera in Patients With Grade 2 and Grade 3 Advanced GEP-NET

NCT03972488Gastro-enteropancreatic Neuroendocrine Tumor

DrugsOctreotide LAR·Lutathera

Advanced Accelerator Applications

Phase 3

226

Clichy, Lyon, Montpellier, Nantes, Villejuif

2020-01-08

Active, closed

Study of Vorasidenib (AG-881) in Participants With Residual or Recurrent Grade 2 Glioma With an IDH1 or IDH2 Mutation (INDIGO)

NCT04164901Grade 2 Glioma, Residual Glioma, Recurrent Glioma

DrugVorasidenib

Institut de Recherches Internationales Servier

Phase 3

331

Lille, Lyon, Marseille, Paris

2020-01-05

Active, closed

Primary Cytoreductive Surgery With or Without Hyperthermic Intraperitoneal Chemotherapy (HIPEC)

NCT03772028Ovarian Cancer

DrugCisplatin

The Netherlands Cancer Institute

Phase 3

538

Besançon, Bordeaux, Lille, Lyon, Montpellier, Nantes, Paris, Strasbourg

2020-01-01

Recruiting

French Colorectal ESD Cohort in Experts Centers

NCT04592003Cancer Colorectal, Polyps Colorectal, Endoscopic Submucosal Resection

University Hospital, Limoges

Observational

1,200

Amiens, Angers, Besançon, Bordeaux, Brest, Dijon, Limoges, Lyon

2020-01-01

Active, closed

Master Protocol to Assess the Safety and Antitumor Activity of Genetically Engineered T Cells in NY-ESO-1 and/or LAGE-1a Positive Solid Tumors

NCT03967223Neoplasms

DrugsFludarabine·Cyclophosphamide

USWM CT, LLC

Phase 2

103

Lyon, Pessac

2019-12-31

Recruiting

A Study of Oral Nuvisertib (TP-3654) in Patients With Myelofibrosis

NCT04176198Myelofibrosis

DrugsMomelotinib·Ruxolitinib

Sumitomo Pharma America, Inc.

Phase 1/2

240

Amiens, Angers, Lyon, Nice, Nîmes, Paris, Poitiers, Villejuif

2019-12-16

Recruiting

Tumoral Bone Strength Assessment by Numerical Simulation Using Quantitative CT : the MEKANOS Study

NCT04170634Metastases to Bone, Metastatic Breast Cancer, Metastatic NSCLC

Hospices Civils de Lyon

Observational

220

Angers, Annecy, Clermont-Ferrand, Contamine-sur-Arve, Lille, Lyon, Paris, Pierre-Bénite

2019-11-28

Recruiting

Hand & Wrist Pyrocarbon Implants Outcomes Clinical Study

NCT04137237Orthopedics

Stryker Trauma and Extremities

Observational

417

Lyon, Paris, Saint-Herblain

2019-11-14

Active, closed

Rollover Study for Continued Safety and Tolerability in Subjects Treated With Spartalizumab Alone or in Combination With Other Study Treatments

NCT04058756Advanced Solid Tumors

DrugSpartalizumab

Novartis Pharmaceuticals

Phase 1

120

Lille, Lyon, Marseille, Villejuif

2019-10-30

Active, closed

Locoregional Treatment and Palbociclib in de Novo, Treatment Naive, Stage IV ER+, HER2- Breast Cancer Patients

NCT03870919Breast Cancer Stage IV, Radiotherapy, Surgery

DrugPalbociclib

UNICANCER

Not applicable

200

Angers, Avignon, Caen, Chalon-sur-Saône, Cholet, Clermont-Ferrand, Dijon, Lyon

2019-10-23

Active, closed

Pre-operative Nivolumab and Ipilimumab, Followed by Post-operative Nivolumab, for MSI/dMMR Oeso-gastric Adenocarcinoma.

NCT04006262Localized Oesogastric Adenocarcimona, MSI and or dMMR

DrugsYervoy·Ipilimumab·Opdivo·Nivolumab

GERCOR - Multidisciplinary Oncology Cooperative Group

Phase 2

Besançon, Créteil, Levallois-Perret, Lille, Lyon, Montpellier, Nantes, Paris

2019-10-23

Recruiting

Septic Shock-induced Immunosuppression

NCT04067674Septic Shock

DrugBlood sampling

Hospices Civils de Lyon

Observational

305

Lyon

2019-10-21

Active, closed

Study Evaluating Cemiplimab Alone and Combined With RP1 in Treating Advanced Squamous Skin Cancer

NCT04050436Cutaneous Squamous Cell Carcinoma, Advanced Cutaneous Squamous Cell Carcinoma, Metastatic Cutaneous Squamous Cell Carcinoma

DrugsVusolimogene Oderparepvec·Cemiplimab

Replimune, Inc.

Phase 2

231

Besançon, Dijon, La Tronche, Lille, Lyon, Marseille, Nice, Paris

2019-10-08

Recruiting

Erectile Dysfunction in Good Prognosis Prostate Cancer : Comparison Between Brachytherapy and Stereotactic Body Radiotherapy

NCT03830788Prostate Cancer

Center Eugene Marquis

Not applicable

240

Albi, Angers, Bordeaux, Dijon, La Garenne-Colombes, Levallois-Perret, Lyon, Montpellier

2019-10-04

Active, closed

A Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer

NCT03975647HER2-positive Breast Cancer

DrugsTucatinib·Trastuzumab emtansine

Seagen, a wholly owned subsidiary of Pfizer

Phase 3

466

Besançon, Caen, Dijon, Lyon, Tours, Le Mans, Brest, Grenoble

2019-10-02

Recruiting

A Study of Tulmimetostat DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and Lymphomas

NCT04104776Advanced Solid Tumor, Diffuse Large B Cell Lymphoma, Lymphoma, T-Cell, Mesothelioma, Malignant

DrugsTulmimetostat·Enzalutamide

Novartis Pharmaceuticals

Phase 1/2

300

Bordeaux, Lille, Lyon, Nantes, Saint-Herblain, Strasbourg, Villejuif

2019-09-18

Active, closed

Safety, Immunogenicity and Preliminary Clinical Activity Study of PDC*lung01 Cancer Vaccine in NSCLC

NCT03970746Non Small Cell Lung Cancer

DrugsPemetrexed·Pembrolizumab

PDC*line Pharma SAS

Phase 1/2

Grenoble, Lyon, Nantes

2019-09-10

Active, closed

Study of TPX-0022 in Patients With Advanced NSCLC, Gastric Cancer or Solid Tumors Harboring Genetic Alterations in MET

NCT03993873Advanced Solid Tumor, Metastatic Solid Tumors, MET Gene Alterations

Turning Point Therapeutics, Inc.

Phase 1

La Tronche, Saint-Mandé, Villejuif, Lyon

2019-09-05

Active, closed

A Study of Lazertinib as Monotherapy or in Combination With Amivantamab in Participants With Advanced Non-small Cell Lung Cancer

NCT04077463Carcinoma, Non-Small-Cell Lung

DrugsLazertinib·Amivantamab·Pemetrexed·Carboplatin

Janssen Research & Development, LLC

Phase 1

701

Bordeaux, Lyon, Marseille, Paris, Poitiers, Saint-Mandé, Villejuif

2019-09-04

Recruiting

Multivirus-specific T-cell Transfer Post SCT vs AdV, CMV and EBV Infections

NCT04832607AdV Infection, EBV Infection, CMV Infection, Stem Cell Transplant Complications

Tobias Feuchtinger

Phase 3

149

Lille, Lyon, Nancy, Paris

2019-08-27

Active, closed

Palbociclib for HR Positive / HER2-negative Isolated Locoregional Recurrence of Breast Cancer

NCT03820830Breast Cancer Recurrent

DrugPalbociclib

ETOP IBCSG Partners Foundation

Phase 3

405

Avignon, Bordeaux, Caen, Cholet, Dijon, Limoges, Lorient, Lyon

2019-08-27

Active, closed

Spearhead 1 Study in Subjects With Advanced Synovial Sarcoma or Myxoid/Round Cell Liposarcoma

NCT04044768Synovial Sarcoma, Myxoid Liposarcoma

USWM CT, LLC

Phase 2

Lyon, Pessac, Villejuif

2019-08-13

Active, closed

A Study of Nivolumab, Nivolumab Plus Ipilimumab, or Investigator's Choice Chemotherapy for the Treatment of Participants With Deficient Mismatch Repair (dMMR)/Microsatellite Instability High (MSI-H) Metastatic Colorectal Cancer (mCRC)

NCT04008030Metastatic Colorectal Cancer

DrugsFluorouracil·Leucovorin·Ipilimumab·Irinotecan

Bristol-Myers Squibb

Phase 3

839

Limoges, Lille, Bayonne, Besançon, Lyon, Marseille, Montpellier, Nantes

2019-08-05

Active, closed

An Intensive Program With Quadruplet Induction and Consolidation Plus Tandem Autologous Stem Cell Transplantation in Newly Diagnosed High Risk Multiple Myeloma Patients

NCT03606577Multiple Myeloma

DrugsCarfilzomib·Daratumumab·Lenalidomide·Dexamethasone

Nantes University Hospital

Phase 2

Nantes, Caen, Dijon, Grenoble, La Roche-sur-Yon, Lille, Lyon, Pessac

2019-07-30

Recruiting

QuantiFERON-CMV Test in a Prediction for Colic Cytomegalovirus Reactivation During Ulcerative Colitis

NCT04030676Cytomegalovirus Infections

DrugBlood samples

Centre Hospitalier Universitaire de Saint Etienne

Not applicable

196

Lyon, Saint-Etienne

2019-07-17

Active, closed

Postoperative Immunotherapy vs Standard Chemotherapy for Gastric Cancer With High Risk for Recurrence

NCT03443856Gastric and Esophagogastric Junction Adenocarcinoma

DrugNivolumab and Ipilimumab

European Organisation for Research and Treatment of Cancer - EORTC

Phase 2

197

Lille, Lyon, Villejuif

2019-07-17

Recruiting

A Clinical and Biological Prospective Database of Patients Treated With Anticancer Immunotherapy and Follow up of Their Immune-related Adverse Events irAE

NCT03989323Cancer

Hospices Civils de Lyon

Observational

2,000

Bron, Lyon, Pierre-Bénite

2019-07-15

Active, closed

A Study of Osimertinib With or Without Chemotherapy as 1st Line Treatment in Patients With Mutated Epidermal Growth Factor Receptor Non-Small Cell Lung Cancer (FLAURA2)

NCT04035486Non-Small Cell Lung Cancer

DrugsPemetrexed/Cisplatin·Pemetrexed/Carboplatin·Osimertinib

AstraZeneca

Phase 3

587

Bordeaux, Lyon, Montpellier, Villejuif

2019-07-02

Recruiting

Observational Study, for Quality Assessment, of Sarcoma in European and Latin American Multidisciplinary NETWORK

NCT04181970Soft-tissue Sarcoma, Gastrointestinal Stromal Tumors, Bone Sarcoma

Grupo Espanol de Investigacion en Sarcomas

Observational

5,000

Lyon

2019-06-30

Recruiting

Study of microRNAs in a Decompensated Cirrhosis

NCT03905746Cirrhosis, Acute Decompensation

Hospices Civils de Lyon

Observational

444

Lyon

2019-06-26

Active, closed

Capivasertib+Paclitaxel as First Line Treatment for Patients With Locally Advanced or Metastatic TNBC

NCT03997123Triple Negative Breast Neoplasms

DrugsCapivasertib·Paclitaxel

AstraZeneca

Phase 3

923

Brest, Lyon, Marseille, Montpellier, Nice, Paris, Saint-Herblain, Villejuif

2019-06-25

Active, closed

Study of Cabozantinib in Combination With Nivolumab and Ipilimumab in Patients With Previously Untreated Advanced or Metastatic Renal Cell Carcinoma

NCT03937219Renal Cell Carcinoma

DrugsCabozantinib·Yervoy·Ipilimumab·Opdivo

Exelixis

Phase 3

855

Bordeaux, Le Mans, Lyon, Montpellier, Nice, Paris, Reims, Rennes

2019-06-25

Active, closed

Adjuvant Palbociclib in Elderly Patients With Breast Cancer

NCT03609047Breast Cancer Stage II, Breast Cancer Stage III

DrugsDoxorubicin/cyclophosphamide·Palbociclib·Paclitaxel

European Organisation for Research and Treatment of Cancer - EORTC

Phase 2

366

Bordeaux, Brou, Caen, Clermont-Ferrand, La Roche-sur-Yon, Lille, Limoges, Lyon

2019-06-14

Active, closed

A Study of Apalutamide in Participants With High-Risk, Localized or Locally Advanced Prostate Cancer Who Are Candidates for Radical Prostatectomy

NCT03767244Prostatic Neoplasms

DrugApalutamide

Janssen Research & Development, LLC

Phase 3

2,517

Angers, Besançon, Bordeaux, Créteil, Lyon, Nantes, Paris, Quint-Fonsegrives

2019-06-11

Active, closed

Study of Adjuvant Cemiplimab Versus Placebo After Surgery and Radiation Therapy in Patients With High Risk Cutaneous Squamous Cell Carcinoma

NCT03969004Cutaneous Squamous Cell Carcinoma

DrugCemiplimab

Regeneron Pharmaceuticals

Phase 3

415

Dijon, Bordeaux, Boulogne-Billancourt, La Tronche, Lille, Lyon, Nantes, Nice

2019-06-04

Recruiting

Expanded Study of the HighLife 28mm Trans-septal Trans-catheter Mitral Valve in Patients With Moderate-severe or Severe Mitral Regurgitation and at High Surgical Risk

NCT04029363Mitral Regurgitation

HighLife SAS

Not applicable

120

Toulouse, Lille, Lyon, Massy, Nantes, Paris, Pessac, Rennes

2019-05-28

Active, closed

A Study to Determine the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of ABBV-927 With ABBV-368, Budigalimab (ABBV-181) and/or Chemotherapy in Participants With Locally Advanced or Metastatic Solid Tumors

NCT03893955Cancer, Advanced Solid Tumors, Triple-Negative Breast Cancer (TNBC), Non-small-cell-lung-cancer (NSCLC)

DrugsABBV-927·Budigalimab·Nab-paclitaxel·Carboplatin

AbbVie

Phase 1

150

Saint-Herblain, Paris, Lyon, Clermont-Ferrand

2019-05-21

Active, closed

IDH1 (AG 120) Inhibitor in Patients With IDH1 Mutated Myelodysplastic Syndrome

NCT03503409Myelodysplastic Syndromes, Acute Myeloid Leukemia

DrugIvosidenib

Groupe Francophone des Myelodysplasies

Phase 2

Angers, Bayonne, Belfort, Caen, Grenoble, Le Mans, Limoges, Lyon

2019-05-14

Recruiting

COLON-IM : Microbiota and Immune Infiltrate in Normal, Dysplastic and Neoplastic Colorectal Tissue

NCT03841799Colorectal Cancer

Centre Leon Berard

Observational

400

Lyon

2019-05-02

Recruiting

LISA Post Market Clinical Follow-Up Study: Documentation of Clinical Outcomes After Surgery With LISA Implant

NCT04631133Chronic Low-back Pain, Herniated Disc, Degenerative Disc Disease, Lumbar Canal Stenosis

BACKBONE

Observational

136

Bordeaux, Lyon, Paris

2019-04-17

Active, closed

Assessing a Regorafenib-irinotecan Combination Versus Regorafenib Alone in Metastatic Colorectal Cancer Patients

NCT03829462Metastatic Colorectal Cancer (mCRC)

DrugsRegorafenib·Irinotecan

Institut du Cancer de Montpellier - Val d'Aurelle

Phase 3

377

Nice, Caen, Rennes, Reims, Perpignan, Lyon, Villejuif, Montpellier

2019-03-28

Active, closed

A Phase 3 Study to Evaluate the Efficacy and Safety of MGL-3196 (Resmetirom) in Patients With NASH and Fibrosis

NCT03900429NASH - Nonalcoholic Steatohepatitis

DrugResmetirom

Madrigal Pharmaceuticals, Inc.

Phase 3

1,759

Strasbourg, Lyon, Clermont-Ferrand, Rennes, Besançon, Lille, Montpellier, Limoges

2019-03-28

Active, closed

Phase III Study in First-line Treatment of Patients With Metastatic Colorectal Cancer Who Are Not Candidate for Intensive Therapy.

NCT03869892Metastatic Colorectal Cancer

DrugsTrifluridine/Tipiracil·Capecitabine

Institut de Recherches Internationales Servier

Phase 3

856

Avignon, Besançon, Brest, Lyon, Montbéliard, Nice, Paris, Pessac

2019-03-21

Active, closed

Prostate Cancer With OligometaSTatic Relapse: Combining Stereotactic Ablative Radiotherapy and Durvalumab (MEDI4736)

NCT03795207Node; Prostate, Bone Metastases, Prostate Cancer Patients

Institut Cancerologie de l'Ouest

Phase 2

Bordeaux, Brest, Dijon, Lille, Lorient, Lyon, Montpellier, Pierre-Bénite

2019-03-21

Active, closed

Efficacy of an Oral Immunomodulatory Nutrient on Survival During Postoperative Concomitant Chemoradiotherapy in Head and Neck Cancer

NCT04001543Head and Neck Squamous Cell Carcinoma

Institut du Cancer de Montpellier - Val d'Aurelle

Not applicable

Lyon, Montpellier

2019-03-14

Active, closed

Treatment Intensification With Temozolomide in Adults With a Glioblastoma

NCT03663725Glioblastoma

DrugStupp protocol

Centre Oscar Lambret

Phase 3

486

Amiens, Caen, Clermont-Ferrand, Colmar, Dijon, Grenoble, Limoges, Lyon

2019-03-13

Active, closed

Durvalumab With Stereotactic Body Radiation Therapy (SBRT) vs Placebo With SBRT in Early Stage Unresected Non-small Cell Lung Cancer (NSCLC) Patients/ Osimertinib Following SBRT in Patients With Early Stage Unresected NSCLC Harboring an EGFR Mutation

NCT03833154Carcinoma, Non-Small-Cell Lung

DrugDurvalumab

AstraZeneca

Phase 3

724

Bron, Dijon, Lyon, Nantes, Pierre-Bénite, Toulouse, Villejuif

2019-03-06

Recruiting

Creation of a Cohort for the Quantitation and Characterization of Circulating Viral RNAs as a New Biomarker of Hepatitis B Functional Cure.

NCT03825458Hepatitis B

Hospices Civils de Lyon

Observational

3,500

Lyon

2019-02-25

Active, closed

Study to Determine the Safety, Tolerability, Pharmacokinetics and Recommended Phase 2 Dose (RP2D) of Livmoniplimab (ABBV-151) as a Single Agent and in Combination With Budigalimab (ABBV-181) in Participants With Locally Advanced or Metastatic Solid Tumors

NCT03821935Advanced Solid Tumors Cancer

DrugsLivmoniplimab·Budigalimab

AbbVie

Phase 1

364

Toulouse, Lyon, Villejuif, Clermont-Ferrand

2019-02-21

Recruiting

Benefit of Intensified Peri-operative Chemotherapy Within High-risk CINSARC Patients With Resectable Soft-tissue Sarcomas

NCT03805022Non-metastatic Soft-tissue Sarcoma, Resectable

DrugsDacarbazine·Ifosfamide·Doxorubicin

Institut Bergonié

Phase 3

351

Bordeaux, Dijon, Limoges, Lyon, Marseille, Montpellier, Saint-Herblain, Strasbourg

2019-02-14

Active, closed

A Study of Ripretinib vs Sunitinib in Advanced GIST Patients After Treatment With Imatinib

NCT03673501Gastrointestinal Stromal Tumors

DrugsRipretinib·Sunitinib

Deciphera Pharmaceuticals, LLC

Phase 3

453

Bordeaux, Dijon, Lille, Lyon, Marseille, Paris, Poitiers, Saint-Herblain

2019-02-08

Active, closed

Detection of Brain Metastasis by MRI in Metastatic Colorectal Cancer Patients

NCT03694938Metastatic Colon Cancer

Poitiers University Hospital

Not applicable

143

Amiens, Lyon, Poitiers, Tours

2019-02-07

Recruiting

Assessment and Follow-up of Surgical Treatment of Hemivertebra in Children

NCT03772119Hemivertebra

University Hospital, Tours

Observational

150

Bordeaux, Grenoble, Lyon, Marseille, Nantes, Nice, Paris, Rennes

2019-02-04

Active, closed

A Study of Niraparib in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for Treatment of Participants With Metastatic Prostate Cancer

NCT03748641Castration-Resistant Prostatic Cancer

DrugsAbiraterone acetate·Niraparib·Prednisone

Janssen Research & Development, LLC

Phase 3

765

Besançon, Bordeaux, Clermont-Ferrand, Lyon, Montpellier, Nancy, Nice, Paris

2019-01-25

Recruiting

Evaluation of Clinical Impact of Interruption VS Maintenance of AI in Patients With Locally Advanced/ Metastatic Low Grade Endometrial Stromal Sarcoma (LGESS)

NCT03624244Low Grade Endometrial Stromal Sarcoma

DrugsExemestane·Anastrozole·Letrozole

Centre Leon Berard

Phase 2

Besançon, Bordeaux, Caen, Clermont-Ferrand, Lille, Limoges, Lyon, Marseille

2019-01-23

Recruiting

Pediatric -Adult Care Transition Program of Patients With Sickle Cell Disease

NCT03786549Sickle Cell Disease

Hospices Civils de Lyon

Not applicable

196

Fort-de-France-La Martinique, Créteil, Le Kremlin-Bicêtre, Lyon, Paris, Pontoise

2019-01-16

Recruiting

Stereotactic Radiotherapy for Cerebral Metastases with Recent Hemorrhagic Signal

NCT03696680Hemorrhagic Brain Metastases

Centre Francois Baclesse

Phase 2

Avranches, Caen, Lyon, Nancy

2019-01-16

Active, closed

Durvalumab Treatment in Combination With Chemotherapy and Bevacizumab, Followed by Maintenance Durvalumab, Bevacizumab and Olaparib Treatment in Advanced Ovarian Cancer Patients

NCT03737643Advanced Ovarian Cancer

DrugsOlaparib·Durvalumab·Paclitaxel·Bevacizumab

AstraZeneca

Phase 3

1,407

Besançon, Bordeaux, Limoges, Lyon, Marseille, Nantes, Paris, Saint-Herblain

2019-01-04

Active, closed

Nivolumab for Pediatric and Adult Relapsing/Refractory ALK+, for Evaluation of Response in Patients With Progressive Disease (Cohort 1) or as Consolidative Immunotherapy in Patients in Complete Remission After Relapse (Cohort 2)

NCT03703050Relapsing/Refractory ALK+ Anaplastic Large Cell Lymphoma

DrugsOpdivo·Nivolumab

Gustave Roussy, Cancer Campus, Grand Paris

Phase 2

Paris, Villejuif, Bordeaux, Créteil, Lille, Lyon, Toulouse, Vandœuvre-lès-Nancy

2019-01-02

Recruiting

Dat'Aids Prevention

NCT03795376HIV Prevention

DatAids

Observational

6,500

Belfort, Besançon, Brest, Clermont-Ferrand, La Roche-sur-Yon, Le Kremlin-Bicêtre, Limoges, Lyon

2019-01-01

Active, closed

A Trial to Evaluate Efficacy and Safety of Ribociclib With Endocrine Therapy as Adjuvant Treatment in Patients With HR+/HER2- Early Breast Cancer

NCT03701334Early Breast Cancer

DrugRibociclib

Novartis Pharmaceuticals

Phase 3

5,101

Nice, Dijon, Limoges, Saint-Cloud, Rennes, Grenoble, Lyon, Amiens

2018-12-07

Active, closed

A Study of Neoadjuvant/Adjuvant Durvalumab for the Treatment of Patients With Resectable Non-small Cell Lung Cancer

NCT03800134Non-Small Cell Lung Cancer

DrugsDurvalumab·Pemetrexed·Gemcitabine·Paclitaxel

AstraZeneca

Phase 3

825

Avignon, Lyon, Nice, Toulon, Vantoux

2018-12-06

Active, closed

Comparison of Intermittent Androgen Deprivation Therapy With or Without Irradiation Recovery in Prostate Cancer Patients

NCT03630666Prostate Cancer, Oligometastasis

Institut Cancerologie de l'Ouest

Not applicable

256

Avignon, Bordeaux, Brest, Chalon-sur-Saône, Clermont-Ferrand, Dijon, Lille, Lyon

2018-12-04

Recruiting

Predictive Value of Progastrin Titer at Diagnosis and of Progastrin Kinetics During Treatment in Cancer Patients

NCT03787056Cancer, Breast Cancer, Gastric Cancer, Renal Cancer

Hospices Civils de Lyon

Not applicable

410

Bron, Lyon, Pierre-Bénite

2018-12-04

Active, closed

Post-Authorization Long-Term Safety Study of LUTATHERA

NCT03691064Neuroendocrine Tumors

DrugLutathera

Advanced Accelerator Applications

Observational

1,014

Clichy, Lyon, Villejuif

2018-11-28

Active, closed

A Study of Abiraterone Acetate Plus Prednisone With or Without Abemaciclib (LY2835219) in Participants With Prostate Cancer

NCT03706365Prostate Cancer

DrugsAbiraterone acetate·Abemaciclib·Prednisone

Eli Lilly and Company

Phase 2/3

393

Lyon, Montpellier, Le Mans, La Roche-sur-Yon, Bordeaux, Créteil

2018-11-26

Active, closed

Immunotherapy With Ipilimumab and Nivolumab Preceded or Not by a Targeted Therapy With Encorafenib and Binimetinib

NCT03235245Unresectable Stage III Melanoma, Stage IV Melanoma

DrugsBinimetinib·Encorafenib·Ipilimumab·Nivolumab

European Organisation for Research and Treatment of Cancer - EORTC

Phase 2

271

Amiens, Besançon, Bordeaux, Clermont-Ferrand, Dijon, Grenoble, Lille, Lyon

2018-10-30

Active, closed

Mifamurtide Combined With Post-operative Chemotherapy for Newly Diagnosed High Risk Osteosarcoma Patients

NCT03643133Osteosarcoma

DrugMifamurtide

UNICANCER

Phase 2

Amiens, Angers, Bordeaux, Caen, La Tronche, Lille, Lyon, Marseille

2018-10-23

Active, closed

Efficacy of Repeat Stereotactic Radiation in Patients With Intraprostatic Tumor Recurrence

NCT03438552Local Recurrence of Malignant Tumor of Prostate

UNICANCER

Not applicable

Caen, Clermont-Ferrand, Dijon, Lille, Lyon, Montpellier, Paris, Rennes

2018-10-18

Recruiting

Medical Economic Evaluation of Bilateral Allograft of Hands and Forearms

NCT02797457Bilateral Traumatic Amputation of Upper Limbs

Hospices Civils de Lyon

Not applicable

Berck, Bruges, Clamart, Lille, Lyon, Miribel, Nancy, Ploemeur

2018-10-16

Active, closed

Study of Telisotuzumab Vedotin (ABBV-399) in Participants With Previously Treated c-Met+ Non-Small Cell Lung Cancer

NCT03539536Non-small Cell Lung Cancer

DrugTelisotuzumab vedotin

AbbVie

Phase 2

270

Marseille, Bordeaux, Lille, Paris, Bron, Lyon, Créteil, Villejuif

2018-10-10

Recruiting

Phase 1 Study of INBRX-109 in Subjects With Locally Advanced or Metastatic Solid Tumors Including Sarcomas

NCT03715933Ewing Sarcoma, Colorectal Adenocarcinoma

DrugsINBRX-109·Temozolomide·Fluorouracil·Leucovorin

Inhibrx Biosciences, Inc

Phase 1

411

Lyon, Villejuif

2018-10-08

Active, closed

A Study of Cabozantinib Compared With Placebo in Subjects With Radioiodine-refractory Differentiated Thyroid Cancer Who Have Progressed After Prior Vascular Endothelial Growth Factor Receptor (VEGFR) -Targeted Therapy

NCT03690388Differentiated Thyroid Cancer

DrugCabozantinib

Exelixis

Phase 3

187

Dijon, Bordeaux, Angers, Marseille, Besançon, Lyon, Nice, Paris

2018-10-05

Active, closed

Phase 3, Multicenter, Randomized Study, Evaluating the Efficacy and Tolerability of Focused HIFU (High Intensity Focused Ultrasound) Therapy Compared to Active Surveillance in Patients With Significant Low Risk Prostate Cancer

NCT03531099Prostate Cancer

Hospices Civils de Lyon

Phase 3

108

Aix-en-Provence, Besançon, Bordeaux, Colmar, Lille, Lyon, Marseille, Paris

2018-10-02

Recruiting

Clinical Evaluation of Laryngeal Transplantation: Study of 3 Patients

NCT02821299Laryngeal Transplantation

Hospices Civils de Lyon

Not applicable

Lyon, Rouen, Saint-Didier-au-Mont-d'Or

2018-09-20

Recruiting

Extension Study for the Port Delivery System With Ranibizumab (Portal)

NCT03683251Neovascular Age-Related Macular Degeneration

DrugPDS Implant with Ranibizumab

Hoffmann-La Roche

Phase 3

1,000

Bordeaux, Lyon, Marseille, Paris

2018-09-20

Active, closed

Study of Immunotherapy in Combination With Chemotherapy in HER2-negative Inflammatory Breast Cancer

NCT03515798Inflammatory Breast Cancer

DrugPembrolizumab

Institut Paoli-Calmettes

Phase 2

Amiens, Avignon, Bordeaux, Caen, Dijon, Lyon, Paris, Rouen

2018-08-29

Recruiting

Long-term Safety and Efficacy Extension Study for Participants With Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab (MK-3475) Study (MK-3475-587/KEYNOTE-587)

NCT03486873Solid Tumors, Hematologic Malignancies

DrugsPembrolizumab/Favezelimab·) Berahyaluronidase alfa·Olaparib·Lenvatinib

Merck Sharp & Dohme LLC

Phase 3

3,500

Nice, Strasbourg, Pessac, Pierre-Bénite, Lyon, Marseille, Caen, Dijon

2018-08-21

Recruiting

Mitotane With or Without Cisplatin and Etoposide After Surgery in Treating Patients With Stage I-III Adrenocortical Cancer With High Risk of Recurrence

NCT03583710ENSAT Stage I Adrenal Cortex Carcinoma, ENSAT Stage II Adrenal Cortex Carcinoma, ENSAT Stage III Adrenal Cortex Carcinoma

DrugsMitotane·Cis-platinum·CDDP·Etoposide

M.D. Anderson Cancer Center

Phase 3

240

Angers, Besançon, Brest, Dijon, Lyon, Marseille, Nantes, Paris

2018-08-20

Active, closed

Safety and Efficacy of Quizartinib in Children and Young Adults With Acute Myeloid Leukemia (AML), a Cancer of the Blood

NCT03793478Acute Myeloid Leukemia

DrugsQuizartinib·Cytarabine·Etoposide·Fludarabine

Daiichi Sankyo

Phase 1/2

Lyon, Paris, Toulouse

2018-08-15

Active, closed

Study of Sacituzumab Govitecan in Participants With Urothelial Cancer That Cannot Be Removed or Has Spread

NCT03547973Metastatic Urothelial Cancer

DrugsDomvanalimab·Zimberelimab·Avelumab·Enfortumab Vedotin

Gilead Sciences

Phase 2

502

Besançon, Bordeaux, Brest, Clermont-Ferrand, La Roche-sur-Yon, Lille, Lyon, Marseille

2018-08-13

Active, closed

Impact of Pegfilgrastim on Trastuzumab Anti-tumor Effect and ADCC in Operable HER2+ Breast Cancer Breast Cancer

NCT03571633HER2-positive Breast Cancer, Operable Breast Cancer

DrugsPegfilgrastim·Trastuzumab·Paclitaxel

Centre Leon Berard

Phase 2

Avignon, Besançon, Clermont-Ferrand, Grenoble, Lyon, Pringy, Saint-Etienne, Sainte-Foy-lès-Lyon

2018-08-06

Active, closed

Clinical and Biological Activity of an Anti-PD-L1 (Atezolizumab) in Operable Localised Soft Tissue Sarcomas Patients to be Treated With Radiotherapy

NCT03474094Sarcoma,Soft Tissue

Centre Leon Berard

Phase 2

Bordeaux, Lille, Lyon, Toulouse, Villejuif

2018-08-01

Recruiting

Long-Term Follow-up Protocol for Participants Treated With Gene-Modified T Cells

NCT03435796Neoplasms

Celgene

Phase 2/3

1,541

Creteil-Paris, Lille, Lyon, Marseille, Montpellier, Nantes, Paris, Pessac

2018-07-19

Active, closed

Efficacy and Safety Study of Tisotumab Vedotin for Patients With Solid Tumors

NCT03485209Colorectal Neoplasms, Carcinoma, Non-Small-Cell Lung, Exocrine Pancreatic Cancer, Carcinoma, Squamous Cell of Head and Neck

DrugsTisotumab Vedotin·Tivdak·Keytruda·Cisplatin

Seagen, a wholly owned subsidiary of Pfizer

Phase 2

350

Besançon, Bourgoin, Lyon, Marseille, Nantes, Pont-de-Vaux, Portes-lès-Valence, Suresnes

2018-06-25

Recruiting

IMRT and Primary Transoral Surgery in the Treatment of Squamous Cell Carcinomas

NCT04224389Squamous Cell Carcinoma

Gustave Roussy, Cancer Campus, Grand Paris

Observational

150

Villejuif, Créteil, Lille, Lyon, Marseille, Montpellier, Nantes, Nice

2018-06-22

Active, closed

Clinical Database of Colorectal Robotic Surgery

NCT04013152Crohn Disease, Polyposis, Ulcerative Colitis, Diverticulitis

Institut du Cancer de Montpellier - Val d'Aurelle

Observational

1,800

Bordeaux, Montpellier, Clermont-Ferrand, Lyon

2018-06-13

Active, closed

Study of Cabozantinib in Combination With Atezolizumab Versus Sorafenib in Participants With Advanced Hepatocellular Carcinoma (HCC) Who Have Not Received Previous Systemic Anticancer Therapy

NCT03755791Hepatocellular Carcinoma

DrugsSorafenib·Cabozantinib·Tecentriq·Atezolizumab

Exelixis

Phase 3

837

Amiens, Besançon, Bondy, Caen, Clichy, Grenoble, Lille, Lyon

2018-06-10

Active, closed

A Study of Runimotamab in Participants With Locally Advanced or Metastatic HER2-Expressing Cancers

NCT03448042Solid Tumors

DrugsTocilizumab·Trastuzumab

Genentech, Inc.

Phase 1

123

Bordeaux, Lyon, Villejuif, Toulouse

2018-06-06

Recruiting

Study of REGN4018 (Ubamatamab) Administered Alone or in Combination With Cemiplimab in Adult Patients With Recurrent Ovarian Cancer or Other Recurrent Mucin-16 Expressing (MUC16+) Cancers

NCT03564340Recurrent Ovarian Cancer, Recurrent Fallopian Tube Cancer, Recurrent Primary Peritoneal Cancer, Recurrent Endometrial Cancer

DrugsUbamatamab·Sarilumab·Cemiplimab·Tocilizumab

Regeneron Pharmaceuticals

Phase 1/2

890

Pierre-Bénite, Dijon, Bordeaux, Caen, Nice, Lyon, Villejuif

2018-05-21

Active, closed

Assessment of Efficacy and Safety of Durvalumab Plus BCG Compared to the Standard Therapy With BCG in Non-muscle Invasive Bladder Cancer

NCT03528694Non-muscle-invasive Bladder Cancer

DrugsBacillus Calmette-Guerin·Durvalumab

AstraZeneca

Phase 3

1,018

Amiens, Angers, Bordeaux, Lyon, Marseille, Montpellier, Strasbourg, Suresnes

2018-05-14

Active, closed

Living After a Rare Cancer of the Ovary: Chronic Fatigue, Quality of Life and Late Effects of Chemotherapy

NCT03418844Germ Cell Tumor, Sex Cord Stromal Tumor, Malignant Non-epithelial Ovarian Tumors

Centre Francois Baclesse

Not applicable

268

Paris, Angers, Besançon, Bordeaux, Bourg-en-Bresse, Caen, Clermont-Ferrand, Lyon

2018-05-07

Recruiting

A Study of Bispecific Antibody MCLA-158 in Patients With Advanced Solid Tumors

NCT03526835Advanced/Metastatic Solid Tumors, Colorectal Cancer, Gastric Cancer, Gastroesophageal-junction Cancer

DrugPetosemtamab

Merus B.V.

Phase 1/2

560

Bordeaux, Lyon, Marseille, Montpellier, Nice, Paris, Rouen

2018-05-02

Active, closed

A Study to Evaluate MEDI5752 in Subjects With Advanced Solid Tumors

NCT03530397Selected Advanced Solid Tumors

DrugsVolrustomig·Nab-paclitaxel·Pemetrexed·Paclitaxel

MedImmune LLC

Phase 1

400

Bordeaux, Lyon, Villejuif

2018-04-24

Active, closed

A Study of Nivolumab in Participants With Hepatocellular Carcinoma Who Are at High Risk of Recurrence After Curative Hepatic Resection or Ablation

NCT03383458Hepatocellular Carcinoma, Liver Cancer

DrugsOpdivo·Nivolumab

Bristol-Myers Squibb

Phase 3

545

Bobigny, Brest, Clermont-Ferrand, Clichy, Créteil, Grenoble, Lille, Lyon

2018-04-18

Active, closed

Development and Progression of Carcinoid Heart Disease in a Cohort of Adult Patients With Neuroendocrine Tumors

NCT03498040Carcinoid Heart Disease

Hospices Civils de Lyon

Observational

670

Amiens, Angers, Bordeaux, Clichy, Dijon, Lille, Lyon, Marseille

2018-04-16

Active, closed

Safety and Efficacy of Pembrolizumab (MK-3475) in Children and Young Adults With Classical Hodgkin Lymphoma (MK-3475-667/KEYNOTE-667)

NCT03407144Hodgkin Lymphoma

DrugsPrednisone/Prednisolone·Vinblastine·Bleomycin·Dacarbazine

Merck Sharp & Dohme LLC

Phase 2

340

Lyon, Marseille, Bordeaux, Lille, Villejuif, Paris

2018-04-09

Active, closed

A Study of Erdafitinib in Participants With Metastatic or Locally Advanced Urothelial Cancer

NCT03473743Urothelial Carcinoma

DrugsErdafitinib·Cetrelimab·Cisplatin·Carboplatin

Janssen Research & Development, LLC

Phase 1/2

125

Angers, Bordeaux, Caen, La Rochelle, Lyon, Marseille, Paris, Strasbourg

2018-04-05

Recruiting

A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Metastatic or Locally Advanced Breast Cancer

NCT03424005Metastatic Breast Cancer

DrugsAtirmociclib·Ipatasertib·Giredestrant·Inavolisib

Hoffmann-La Roche

Phase 1/2

1,132

Lyon, Montpellier, Toulouse, Villejuif

2018-03-30

Recruiting

Autoreactive Anti-Ro/SSA IgE To Determine Primary SjögRen's Syndrome's Disease Activity

NCT03003572Primary Sjögren's Syndrome

Centre Hospitalier Universitaire de Saint Etienne

Observational

185

Bourgoin, Clermont-Ferrand, Grenoble, Lyon, Reims, Saint-Etienne

2018-03-27

Active, closed

Safety and Pharmacokinetics of ODM-208 in Patients With Metastatic Castration-resistant Prostate Cancer

NCT03436485Prostate Cancer Metastatic

DrugsOpevesostat·Midazolam

Orion Corporation, Orion Pharma

Phase 1/2

204

Bordeaux, Lyon, Marseille, Strasbourg, Suresnes, Villejuif

2018-03-19

Active, closed

To Assess Safety and Efficacy of Agents Targeting DNA Damage Repair With Olaparib Versus Olaparib Monotherapy.

NCT03330847Metastatic Triple Negative Breast Cancer

DrugCeralasertib

AstraZeneca

Phase 2

273

Angers, Besançon, Bordeaux, Caen, Lille, Lyon, Marseille, Montpellier

2018-03-07

Recruiting

Dabrafenib and/or Trametinib Rollover Study

NCT03340506Melanoma, Non Small Cell Lung Cancer, Solid Tumor, Rare Cancers

DrugsDabrafenib·Trametinib

Novartis Pharmaceuticals

Phase 4

100

Lyon, Nantes, Paris, Villejuif

2018-01-26

Recruiting

The EMPOWER Trial - The Carillon Mitral Contour System® in Treating Heart Failure With FMR

NCT03142152Functional Mitral Regurgitation, Heart Failure, Mitral Valve Insufficiency, Heart Diseases

Cardiac Dimensions, Inc.

Not applicable

300

Clermont-Ferrand, Lille, Lyon, Montpellier, Paris

2018-01-01

Recruiting

Randomized Carbon Ions vs Standard Radiotherapy for Radioresistant Tumors

NCT02838602Malignant Tumors as Chordoma, Adenoid Cystic Carcinoma and Sarcoma

Hospices Civils de Lyon

Not applicable

250

Amiens, Caen, Clermont-Ferrand, Dijon, Grenoble, Lille, Lyon, Marseille

2017-12-23

Active, closed

Talazoparib + Enzalutamide vs. Enzalutamide Monotherapy in mCRPC

NCT03395197mCRPC

Pfizer

Phase 3

1,054

Le Mans, Bayonne, Bordeaux, La Roche-sur-Yon, Lyon, Montpellier, Paris, Strasbourg

2017-12-18

Active, closed

Study of Seladelpar in Participants With Primary Biliary Cholangitis (PBC)

NCT03301506Primary Biliary Cirrhosis

DrugSeladelpar

Gilead Sciences

Phase 3

340

Lyon, Paris

2017-12-12

Active, closed

iRECIST Evaluation's Relevance for DCR in MMR/MSI Metastatic Colorectal Cancer Patients on Nivolumab and Ipilimumab

NCT03350126Metastatic Cancer Colorectal

DrugsIpilimumab·Nivolumab

GERCOR - Multidisciplinary Oncology Cooperative Group

Phase 2

Avignon, Besançon, Créteil, Levallois-Perret, Lyon, Nantes, Paris, Poitiers

2017-12-04

Active, closed

Cognitive Behavioural Group Therapy Versus Individual Supportive Therapy for the Prevention of Repeat Suicide Attempts

NCT02664701Suicidal Ideation, Suicide, Attempt

Centre Hospitalier Universitaire de Nīmes

Not applicable

240

Clermont-Ferrand, Lyon, Montpellier, Nîmes, Paris, Poitiers, Saint-Cyr-sur-Loire, Strasbourg

2017-10-17

Recruiting

Evolution of the Therapeutic Care in Lung Cancer in France Since 2015 (ESME LC)

NCT03848052Lung Cancer

UNICANCER

Observational

75,000

Angers, Bordeaux, Caen, Clermont-Ferrand, Créteil, Dijon, Lille, Lyon

2017-10-02

Recruiting

APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors

NCT03175224Solid Tumors, Advanced Cancer, Renal Cancer, Gastric Cancer

DrugsBozitinib·Vebreltinib

Apollomics Inc.

Phase 2

497

Brest, Lyon, Marseille, Paris, Villejuif

2017-09-27

Active, closed

Trial Comparing Irradiation Plus Long Term Adjuvant Androgen Deprivation With GnRH Antagonist Versus GnRH Agonist Plus Flare Protection in Patients With Very High Risk Localized or Locally Advanced Prostate Cancer

NCT02799706Prostate Cancer

DrugDegarelix

European Organisation for Research and Treatment of Cancer - EORTC

Phase 3

885

Amiens, Arras, Bayonne, Beuvry, Grenoble, Lyon, Nantes, Paris

2017-09-25

Active, closed

A Study to Evaluate the Efficacy and Safety of Multiple Targeted Therapies as Treatments for Participants With Non-Small Cell Lung Cancer (NSCLC)

NCT03178552Non-Small Cell Lung Cancer

DrugsCobimetinib·Divarasib·Vemurafenib·Entrectinib

Hoffmann-La Roche

Phase 2/3

1,000

Bordeaux, Caen, Lille, Lyon, Nîmes, Nouilly, Paris, Poitiers

2017-09-22

Active, closed

Phase 1 Study of CK-301 (Cosibelimab) as a Single Agent in Subjects With Advanced Cancers

NCT03212404Lung Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Small Cell, Malignant Mesothelioma, Advanced

Checkpoint Therapeutics, Inc.

Phase 1

272

Besançon, Bordeaux, Grenoble, Lyon, Nice

2017-09-20

Active, closed

Study of RP1 Monotherapy and RP1 in Combination With Nivolumab (IGNYTE)

NCT03767348Non-Small Cell Lung Cancer (NSCLC), Microsatellite Instability-High (MSI-H), Non-melanoma Skin Cancer (NMSC), Cutaneous Melanoma

DrugsVusolimogene Oderparepvec·Opdivo·Nivolumab

Replimune, Inc.

Phase 2

340

Besançon, Bordeaux, Dijon, Lyon, Marseille, Nice, Paris, Villejuif

2017-09-20

Active, closed

A Study in Participants Previously Enrolled in a Genentech- and/or F. Hoffmann-La Roche Ltd-Sponsored Atezolizumab Study (IMbrella A)

NCT03148418Cancer

DrugsTecentriq·Avastin·Atezolizumab·Bevacizumab

Hoffmann-La Roche

Phase 3

382

Besançon, Grenoble, Lyon, Marseille, Nantes, Nice, Paris, Pierre-Bénite

2017-09-20

Active, closed

Study of Cabozantinib Alone or in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors

NCT03170960Urothelial Carcinoma, Renal Cell Carcinoma, Non-Small Cell Lung Cancer, Castration-resistant Prostate Cancer

DrugsCabozantinib·Tecentriq·Atezolizumab

Exelixis

Phase 1

914

La Roche-sur-Yon, Villejuif, Bordeaux, Brest, Caen, Le Mans, Lille, Lyon

2017-09-05

Active, closed

Phase I/IIa Study of Concomitant Radiotherapy With Olaparib and Temozolomide in Unresectable High Grade Gliomas Patients

NCT03212742Malignant Gliomas, Radiotherapy, PARP Inhibitor

DrugsTemozolomide·Olaparib

Centre Francois Baclesse

Phase 1/2

Amiens, Angers, Bordeaux, Caen, Le Havre, Lorient, Lyon, Paris

2017-09-04

Active, closed

Phase Ib/II of TG4001 and Avelumab in HPV16 Positive R/M Cancers

NCT03260023HPV-Related Carcinoma, HPV-Related Cervical Carcinoma, HPV-Related Anal Squamous Cell Carcinoma, HPV-Related Penile Squamous Cell Carcinoma

DrugAvelumab

Transgene

Phase 1/2

143

Angers, Besançon, Bordeaux, Colmar, Dijon, Lyon, Marseille, Paris

2017-09-01

Active, closed

Endocrine Therapy With or Without Abemaciclib (LY2835219) Following Surgery in Participants With Breast Cancer

NCT03155997Breast Cancer

DrugAbemaciclib

Eli Lilly and Company

Phase 3

5,637

Lyon, Brest, La Chaussée-Saint-Victor, Dijon, Plérin, Besançon, Rennes, Montpellier

2017-07-12

Active, closed

QUALIOR Feasibility and Efficacy of a Supervised Home-based Standard Physical Exercise Program

NCT03169075Home Based Standardised Adapted Physical Activity Programme, Patients Taking Oral Targeted Therapy for Metastatic Cancer

UNICANCER

Not applicable

190

Angers, Annecy, Besançon, Caen, Cholet, Grenoble, La Roche-sur-Yon, Lyon

2017-07-11

Recruiting

A 3 Years Naturalistic Cohort Survey Of Virtue® Male Sling System For Male Stress Urinary Incontinence

NCT04098822Urinary Incontinence, Stress

Coloplast A/S

Observational

130

Angers, Besançon, Caen, Chalon-sur-Saône, Créteil, Lille, Lorient, Lyon

2017-06-29

Recruiting

Breast Implant-associated Anaplastic Large Cell Lymphoma (BIA-ALCL) Registry

NCT04220970Anaplastic Large Cell Lymphoma Associated With Breast Implants (BIA-ALCL)

The Lymphoma Academic Research Organisation

Observational

150

Avignon, Bordeaux, Brest, Colmar, Créteil, Dijon, Lille, Lyon

2017-06-07

Active, closed

Dose Escalation Study of Teclistamab, a Humanized BCMA*CD3 Bispecific Antibody, in Participants With Relapsed or Refractory Multiple Myeloma

NCT03145181Hematological Malignancies

DrugTeclistamab

Janssen Research & Development, LLC

Phase 1

302

Lyon, Tours

2017-05-16

Active, closed

A Study of Selpercatinib (LOXO-292) in Participants With Advanced Solid Tumors, RET Fusion-Positive Solid Tumors, and Medullary Thyroid Cancer (LIBRETTO-001)

NCT03157128Non-Small Cell Lung Cancer, Medullary Thyroid Cancer, Colon Cancer, Any Solid Tumor

DrugSelpercatinib

Eli Lilly and Company

Phase 1/2

857

Bordeaux, Lyon, Marseille, Montpellier, Villejuif, Paris

2017-05-02

Recruiting

DCP (RaDiCo Cohort) (RaDiCo-DCP)

NCT05951478Primary Ciliary Dyskinesia

Institut National de la Santé Et de la Recherche Médicale, France

Observational

300

Besançon, Bordeaux, Caen, Créteil, Dijon, Le Kremlin-Bicêtre, Lille, Lyon

2017-05-01

Active, closed

Tracking Triple-negative Breast Cancer Evolution Through Therapy

NCT03077776Triple-Negative Breast Neoplasm

UNICANCER

Not applicable

149

Clermont-Ferrand, Dijon, Lyon, Marseille, Nantes, Rennes, Strasbourg, Vandœuvre-lès-Nancy

2017-04-14

Recruiting

IDMet (RaDiCo Cohort) (RaDiCo-IDMet)

NCT05945576Silver Russell Syndrome, Beckwith-Wiedemann Syndrome, Transient Neonatal Diabetes Mellitus, Angelman Syndrome

Institut National de la Santé Et de la Recherche Médicale, France

Observational

2,000

Angers, Besançon, Clermont-Ferrand, Le Kremlin-Bicêtre, Lille, Limoges, Lyon, Marseille

2017-03-10

Active, closed

A Study of ABBV-927 and ABBV-181, an Immunotherapy, in Participants With Advanced Solid Tumors

NCT02988960Advanced Solid Tumors Cancer

DrugsABBV-927·Budigalimab

AbbVie

Phase 1

163

Bordeaux, Montpellier, Lyon, Villejuif

2017-02-22

Active, closed

Study of Vimseltinib (DCC-3014) in Patients With Advanced Tumors and Tenosynovial Giant Cell Tumor

NCT03069469Advanced Malignant Neoplasm, Pigmented Villonodular Synovitis, Giant Cell Tumor of Tendon Sheath, Tenosynovial Giant Cell Tumor

DrugVimseltinib

Deciphera Pharmaceuticals, LLC

Phase 1/2

120

Lyon, Paris

2017-02-16

Active, closed

Nonfunctioning Small (≤2 cm) Neuroendocrine Pancreatic Incidentaloma

NCT03022188Neuroendocrine Tumors

Société Française d'Endoscopie Digestive

Observational

100

Amiens, Angers, Besançon, Bordeaux, Clichy, Dijon, Lyon, Marseille

2017-01-10

Recruiting

Prospective Biobanking Study in Cancer Patients Aiming at Better Understand the Link Between the Molecular Alterations of the Tumor Itself, Its Microenvironment and Immune Response (SCANDARE)

NCT03017573Ovarian Cancer, Triple-Negative Breast Cancer, Head and Neck Cancer, Cervical Cancer

Institut Curie

Not applicable

1,050

Bordeaux, Lille, Lyon, Paris, Saint-Cloud, Vandœuvre-lès-Nancy

2017-01-06

Active, closed

Feasibility of Molecular Biology in Pancreatic Cyst Tumors

NCT03305146Pancreatic Cyst, Pancreas Cyst, Serous Cystadenoma, Mucinous Cystadenoma

Hospital St. Joseph, Marseille, France

Not applicable

Charenton-le-Pont, Limoges, Lyon, Marseille, Nantes, Nice, Paris, Vichy

2017-01

Active, closed

Open-Label, Randomised, Multi-Drug, Biomarker-Directed, Phase 1b Study in Pts w/ Muscle Invasive Bladder Cancer

NCT02546661Muscle Invasive Bladder Cancer

DrugsDanvatirsen·Fexagratinib·Vistusertib·Adavosertib

AstraZeneca

Phase 1

117

Bordeaux, Caen, Lyon, Marseille, Saint-Herblain, Toulouse

2016-12-28

Active, closed

A Study for Subjects With Prostate Cancer Who Previously Participated in an Enzalutamide Clinical Study

NCT02960022Prostate Cancer

DrugsLeuprolide Acetate·Xtandi·Abiraterone acetate·Enzalutamide

Astellas Pharma Global Development, Inc.

Phase 2

900

Bordeaux, La Roche-sur-Yon, Lille, Lyon, Montpellier, Nîmes, Paris, Saint-Herblain

2016-12-22

Active, closed

Management of Symptomatic Advanced Pancreatic Adenocarcinoma

NCT02979483Pancreas, Management Supportive Care Program

GERCOR - Multidisciplinary Oncology Cooperative Group

Not applicable

110

Avignon, Clichy, Créteil, Levallois-Perret, Lyon, Mont-de-Marsan, Paris, Thonon-les-Bains

2016-12-19

Active, closed

Ribociclib (LEE011) Rollover Study for Continued Access

NCT02934568Continued Access to Study Treatment(s), Cancers With a Mass, Bulky Tumor, Nodule, Lump, Advanced Cancer, Advanced Solid Tumors, Advanced Solid Malignancies

DrugRibociclib

Novartis Pharmaceuticals

Phase 2

Lyon, Villejuif

2016-12-15

Active, closed

SEDVasc (RaDiCo Cohort) (RaDiCo-SEDVasc)

NCT05976841Ehlers-Danlos Syndrome, Vascular Type

Institut National de la Santé Et de la Recherche Médicale, France

Observational

340

Angers, Bordeaux, Brest, Caen, Clermont-Ferrand, Grenoble, Lille, Lyon

2016-12-05

Recruiting

Second STOP After Pioglitazone Priming in CML Patients

NCT02889003Chronic Myeloid Leukemia (CML)

DrugPioglitazone

Versailles Hospital

Phase 2

Le Chesnay, Le Kremlin-Bicêtre, Lyon, Nantes, Rennes, Toulouse

2016-12

Active, closed

Study to Evaluate the Efficacy, Safety, and Tolerability of Long-acting Intramuscular Cabotegravir and Rilpivirine for Maintenance of Virologic Suppression Following Switch From an Integrase Inhibitor in HIV-1 Infected Therapy Naive Participants

NCT02938520HIV Infections

DrugsCabotegravir (CAB)·Rilpivirine (RPV)·Rilpivirine·Cabotegravir

ViiV Healthcare

Phase 3

631

Bobigny, Lyon, Marseille, Paris

2016-10-27

Active, closed

Evaluation of Lymphadenectomy and Chemotherapy TIP on Inguinal Lymph Nodes in Squamous Cell Carcinoma of the Penis

NCT02817958Penile Cancer, Squamous Carcinoma

UNICANCER

Phase 2

Angers, Besançon, Bordeaux, Caen, Clermont-Ferrand, Limoges, Lyon, Marseille

2016-10-17

Active, closed

Lenvatinib/Everolimus or Lenvatinib/Pembrolizumab Versus Sunitinib Alone as Treatment of Advanced Renal Cell Carcinoma

NCT02811861Renal Cell Carcinoma

DrugsSunitinib·Everolimus·Lenvatinib·Pembrolizumab

Eisai Inc.

Phase 3

1,069

Angers, Dijon, Le Mans, Lyon, Montpellier, Paris, Saint-Herblain, Strasbourg

2016-10-13

Recruiting

Management and Clinical Outcomes of Patients With Severe Mitral Valve Disease Not Suitable for Surgery

NCT02925819Mitral Valve Disease

French Cardiology Society

Observational

500

Lyon, Nantes, Paris

2016-10

Active, closed

Health Data from Well on My Legs Program

NCT06659484Sarcopenia, Frailty, Physical Inactivity, Fear

Hospices Civils de Lyon

Observational

1,600

Lyon

2016-09-20

Recruiting

European Proof-of-Concept Therapeutic Stratification Trial of Molecular Anomalies in Relapsed or Refractory Tumors

NCT02813135Pediatric Cancer

DrugsPeposertib·Vistusertib·Adavosertib·Capmatinib

Gustave Roussy, Cancer Campus, Grand Paris

Phase 1/2

472

Villejuif, Angers, Bordeaux, Lille, Lyon, Marseille, Nantes, Paris

2016-08-03

Active, closed

STAR-LIFE Registry: STARflo Glaucoma Implant Clinical Experience Program

NCT02825264Open Angle Glaucoma

iSTAR Medical

Observational

Lyon, Paris

2016-07

Recruiting

CINSARC Signature and Correlation With Hemotherapy Efficacy in Soft-tissue Sarcomas. A Biomarker Study.

NCT02789384Soft-tissue Sarcomas

Institut Bergonié

Not applicable

205

Bordeaux, Dijon, Lille, Lyon, Marseille, Nantes, Paris, Toulouse

2016-06

Active, closed

Study of Amivantamab, a Human Bispecific EGFR and cMet Antibody, in Participants With Advanced Non-Small Cell Lung Cancer

NCT02609776Non-Small-Cell Lung Cancer

DrugsLazertinib·Amivantamab·Pemetrexed·Carboplatin

Janssen Research & Development, LLC

Phase 1

751

Bordeaux, Dijon, Lyon, Marseille, Paris, Saint-Herblain, Villejuif

2016-05-24

Active, closed

A Study of Ramucirumab (LY3009806) or Merestinib (LY2801653) in Advanced or Metastatic Biliary Tract Cancer

NCT02711553Biliary Tract Cancer, Metastatic Cancer, Advanced Cancer

DrugsRamucirumab·Gemcitabine·Cisplatin

Eli Lilly and Company

Phase 2

309

Lyon, Bordeaux, Besançon, Lille, Montpellier, Nice, Villejuif

2016-05-19

Active, closed

Study Of Entrectinib (Rxdx-101) in Children and Adolescents With Locally Advanced Or Metastatic Solid Or Primary CNS Tumors And/Or Who Have No Satisfactory Treatment Options

NCT02650401Solid Tumors, CNS Tumors

DrugEntrectinib

Hoffmann-La Roche

Phase 1/2

Lyon, Marseille

2016-05-03

Active, closed

A Study of the ReCor Medical Paradise System in Clinical Hypertension

NCT02649426Hypertension, Vascular Diseases

ReCor Medical, Inc.

Not applicable

282

Bordeaux, Lille, Lyon, Paris, Toulouse

2016-03

Active, closed

Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (Fusions)

NCT02568267Breast Cancer, Cholangiocarcinoma, Colorectal Cancer, Head and Neck Neoplasms

DrugEntrectinib

Hoffmann-La Roche

Phase 2

534

Angers, Bordeaux, Lyon, Marseille, Montpellier, Paris, Toulouse, Villejuif

2015-11-19

Active, closed

Study of MEDI4736 (Durvalumab) With or Without Tremelimumab Versus Standard of Care Chemotherapy in Urothelial Cancer

NCT02516241Urothelial Cancer

DrugsTremelimumab·Durvalumab·Gemcitabine·Cisplatin

AstraZeneca

Phase 3

1,126

Bordeaux, Caen, Lyon, Marseille, Paris, Poitiers, Suresnes, Toulouse

2015-11-02

Active, closed

AZD9291 Versus Placebo in Patients With Stage IB-IIIA Non-small Cell Lung Carcinoma, Following Complete Tumour Resection With or Without Adjuvant Chemotherapy.

NCT02511106Stage IB-IIIA Non-small Cell Lung Carcinoma

DrugOsimertinib

AstraZeneca

Phase 3

682

Bron, Lille, Limoges, Lyon, Paris

2015-10-21

Active, closed

Phase III Radium 223 mCRPC-PEACE III

NCT02194842Prostate Cancer

DrugsRa223·Enzalutamide

European Organisation for Research and Treatment of Cancer - EORTC

Phase 3

446

Angers, Caen, Créteil, Lyon, Montpellier, Saint-Herblain, Strasbourg, Villejuif

2015-10

Active, closed

Standard-Dose Combination Chemotherapy or High-Dose Combination Chemotherapy and Stem Cell Transplant in Treating Patients With Relapsed or Refractory Germ Cell Tumors

NCT02375204Germ Cell Tumor, Teratoma, Choriocarcinoma, Germinoma

DrugsPegylated G-CSF·Ifosfamide·G-Csf·CDDP

Alliance for Clinical Trials in Oncology

Phase 3

420

Lyon, Marseille, Paris, Strasbourg, Toulouse, Vandœuvre-lès-Nancy, Villejuif

2015-08-06

Active, closed

Phase III Open Label First Line Therapy Study of MEDI 4736 (Durvalumab) With or Without Tremelimumab Versus SOC in Non Small-Cell Lung Cancer (NSCLC)

NCT02453282Non-Small-Cell Lung Carcinoma NSCLC

DrugsTremelimumab·Durvalumab·Pemetrexed·Gemcitabine

AstraZeneca

Phase 3

1,118

Bordeaux, Brest, Créteil, Lille, Lyon, Marseille

2015-07-21

Recruiting

LIquid BIopsies in Patients Presenting Non-small Cell Lung Cancer

NCT02511288Carcinoma, Non-Small-Cell Lung

Centre Leon Berard

Observational

900

Annecy, Bourg-en-Bresse, Bron, Grenoble, Lyon, Saint-Priest-en-Jarez, Villefranche-sur-Saône

2015-07

Active, closed

Safety of a Boost (CXB or EBRT) in Combination With Neoadjuvant Chemoradiotherapy for Early Rectal Adenocarcinoma

NCT02505750Rectal Neoplasms

DrugCapecitabine

Centre Antoine Lacassagne

Phase 3

148

Lyon, Besançon, Reims, Marseille, Mâcon, Nice, Pierre-Bénite, Saint-Priest-en-Jarez

2015-06-24

Recruiting

Surgery for Recurrent Glioblastoma

NCT02394626Glioblastoma

Insel Gruppe AG, University Hospital Bern

Phase 2

120

Dijon, Lyon, Marseille, Nice, Paris, Saint-Etienne, Strasbourg, Tours

2015-05-01

Active, closed

An Efficacy and Safety Study of Erdafitinib (JNJ-42756493) in Participants With Urothelial Cancer

NCT02365597Urothelial Cancer

DrugsErdafitinib·Midazolam·Metformin

Janssen Research & Development, LLC

Phase 2

239

Angers, Bordeaux, Caen Cédex 05, Dijon, Lyon, Nice, Nîmes, Paris

2015-04-22

Active, closed

A Study of Two Different Doses of Cabozantinib (XL184) in Progressive, Metastatic Medullary Thyroid Cancer

NCT01896479Medullary Thyroid Cancer

Exelixis

Phase 4

247

Bordeaux, Angers, Lyon, Villejuif, Dijon, Paris, Strasbourg

2015-02-25

By invitation

Registry of Patients With Hypophosphatasia

NCT02306720Hypophosphatasia (HPP)

Alexion Pharmaceuticals, Inc.

Observational

1,571

Toulouse, Lille, Paris, Poitiers, Lyon, Le Kremlin-Bicêtre

2015-01-20

Active, closed

A Study of Zenocutuzumab (MCLA-128) in Patients With Solid Tumors Harboring an NRG1 Fusion (eNRGy)

NCT02912949Solid Tumours Harboring NRG1 Fusion, NSCLC Harboring NRG1 Fusion, Pancreatic Cancer Harboring NRG1 Fusion, NRG1 Fusion

DrugBispecific

Partner Therapeutics, Inc.

Phase 2

250

Lyon, Paris

2015-01

Active, closed

Cabozantinib S-malate in Treating Patients With Relapsed Osteosarcoma or Ewing Sarcoma

NCT02243605Metastatic Ewing Sarcoma, Metastatic Osteosarcoma, Recurrent Ewing Sarcoma, Recurrent Osteosarcoma

DrugsCabozantinib S-malate·Cabozantinib

National Cancer Institute (NCI)

Phase 2

Bordeaux, Dijon, Lille, Lyon, Marseille, Nice, Paris, Saint-Herblain

2014-12-19

Active, closed

Pregnancy Outcome and Safety of Interrupting Therapy for Women With Endocrine Responsive Breast Cancer

NCT02308085Early Breast Cancer

ETOP IBCSG Partners Foundation

Not applicable

518

Bordeaux, Lille, Lyon, Paris

2014-12-04

Active, closed

An Efficacy and Safety Study of Apalutamide (JNJ-56021927) in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone in Participants With Chemotherapy-naive Metastatic Castration-resistant Prostate Cancer (mCRPC)

NCT02257736Prostatic Neoplasms

DrugsZytiga·Apalutamide·Abiraterone acetate·Prednisone

Aragon Pharmaceuticals, Inc.

Phase 3

982

Angers, Caen, Dijon, Le Mans, Lyon, Montpellier, Paris, Saint-Herblain

2014-11-26

Active, closed

A Study of Nonsteroidal Aromatase Inhibitors Plus Abemaciclib (LY2835219) in Postmenopausal Women With Breast Cancer

NCT02246621Breast Cancer

DrugsAnastrozole·Abemaciclib·Letrozole

Eli Lilly and Company

Phase 3

493

Bordeaux, Lyon, Brest, Dijon, Saint-Brieuc, Montpellier, Saint-Herblain, Nancy

2014-11-06

Recruiting

Trabectedin Plus Radiotherapy in Soft Tissue Sarcoma Patients

NCT02275286Liposarcoma, Myxoid, Sarcoma, Soft Tissue, Leiomyosarcoma, Liposarcoma

DrugTrabectedin

Grupo Espanol de Investigacion en Sarcomas

Phase 1/2

199

Bordeaux, Lyon

2014-11

Recruiting

Predictive Factors and Autonomy Level Change

NCT02302482Memory Impairment

Hospices Civils de Lyon

Not applicable

10,860

Caluire-et-Cuire, Lyon

2014-11

Active, closed

Ascending Doses of Ceralasertib in Combination With Chemotherapy and/or Novel Anti Cancer Agents

NCT02264678Adv Solid Malig - H&N SCC, ATM Pro / Def NSCLC, Gastric, Breast and Ovarian Cancer

DrugsSaruparib·Olaparib·Durvalumab·Carboplatin

AstraZeneca

Phase 1

358

Bordeaux, Lyon, Saint-Herblain, Villejuif

2014-10-31

Recruiting

Prospective Evaluation of the Efficacy of Sirolimus (Rapamune®) in the Treatment of Severe Arteriovenous Malformations

NCT02042326Arteriovenous Malformations

DrugsRapamycin·Sirolimus

Centre Hospitalier Universitaire, Amiens

Phase 2

Amiens, Bordeaux, Dijon, Lille, Lyon, Marseille, Montpellier, Nancy

2014-09-12

Recruiting

Evolution of the Therapeutic Care in Metastatic Breast Cancer From 2008

NCT03275311Metastatic Breast Cancer

UNICANCER

Observational

42,000

Angers, Bordeaux, Caen, Clermont-Ferrand, Dijon, Lille, Lyon, Marseille

2014-07

Active, closed

Biological and Clinical Database for Pancreatic Adenocarcinoma

NCT02818829Pancreatic Adenocarcinoma

University Hospital, Toulouse

Observational

1,700

Bordeaux, Clichy, Lille, Lyon, Marseille, Montpellier, Nice, Paris

2014-05

Recruiting

Antiangiogenic Therapy for Children With Recurrent Medulloblastoma, Ependymoma, ATRT and Rare CNS Tumors

NCT01356290Medulloblastoma Recurrent, Ependymoma Recurrent, ATRT Recurrent, Rare CNS Tumor Recurrent

DrugsThalidomide·Celecoxib·Temozolomide·Cytarabine

Medical University of Vienna

Phase 2

232

Lille, Lyon

2014-04

Recruiting

Registry of Deep Brain Stimulation With the VERCISE™ System: Vercise DBS Registry

NCT02071134Parkinson's Disease

Boston Scientific Corporation

Observational

1,500

Créteil, Lyon, Marseille, Paris, Rennes

2014-03-04

Recruiting

Adapting Treatment to the Tumor Molecular Alterations for Patients With Advanced Solid Tumors: MyOwnSpecificTreatment

NCT02029001Malignant Solid Neoplasms

DrugsLapatinib·Pazopanib·Nilotinib·Sorafenib

Centre Leon Berard

Phase 2

900

Bordeaux, Lyon, Marseille, Paris, Strasbourg, Toulouse

2014-03

Active, closed

Phase II Study of Chlorambucil and Subcutaneous Rituximab in Patients With Extranodal MALT Lymphoma

NCT01808599MALT Lymphoma

DrugsChlorambucil·Rituximab

International Extranodal Lymphoma Study Group (IELSG)

Phase 2

112

Créteil, Dijon, Estaing, Grenoble, Lille, Lyon, Marseille, Montpellier

2013-12

Active, closed

Olaparib Treatment in BRCA Mutated Ovarian Cancer Patients After Complete or Partial Response to Platinum Chemotherapy

NCT01874353Platinum Sensitive, BRCA Mutated, Relapsed Ovarian Cancer, Following Complete or Partial Response to Platinum Based Chemotherapy

DrugOlaparib

AstraZeneca

Phase 3

327

Bordeaux, Caen, Lyon, Nantes, Paris, Pierre-Bénite, Saint-Cloud, Toulouse

2013-09-03

Active, closed

Olaparib Maintenance Monotherapy in Patients With BRCA Mutated Ovarian Cancer Following First Line Platinum Based Chemotherapy.

NCT01844986Newly Diagnosed, Advanced Ovarian Cancer, FIGO Stage III-IV, BRCA Mutation

DrugOlaparib

AstraZeneca

Phase 3

450

Bordeaux, Caen, Lyon, Nantes, Paris, Vandœuvre-lès-Nancy, Villejuif

2013-08-26

Recruiting

Iatrogenic Effects of Treatment for Childhood Cancer Constitution of a Biological Samples Bank

NCT02666625Paediatric Malignancies

Gustave Roussy, Cancer Campus, Grand Paris

Observational

10,000

Villejuif, Lyon, Paris

2013-07-23

Recruiting

Allogeneic Stem Cell Transplantation for Children and Adolescents With Acute Lymphoblastic Leukaemia

NCT01949129Acute Lymphoblastic Leukaemia

DrugsGrafalon·Treosulfan·Thiotepa·Busulfan

St. Anna Kinderkrebsforschung

Phase 2/3

1,800

Bordeaux, Clermont-Ferrand, Grenoble, Lille, Lyon, Marseille, Montpellier, Nancy

2013-04

Active, closed

Safety Study of Adding Everolimus to Adjuvant Hormone Therapy in Women With High Risk of Relapse, ER+ and HER2- Primary Breast Cancer, Free of Disease After Receiving at Least One Year of Adjuvant Hormone Therapy

NCT01805271Primary Non-metastatic Breast Cancer, Who Remain Disease-free

DrugEverolimus

UNICANCER

Phase 3

1,278

Lyon, Villejuif

2013-03

Active, closed

French Database of Occipital Nerves Stimulation in the Treatment of Refractory Chronic Headache Disorders

NCT01842763Refractory Chronic Headache Disorders

Centre Hospitalier Universitaire de Nice

Observational

246

Colmar, Clermont-Ferrand, Épagny, Grenoble, Lille, Limoges, Lyon, Marseille

2013-03

Recruiting

Patient Retrospective Outcomes (PRO)

NCT01550575Chronic Pain

Boston Scientific Corporation

Observational

15,000

Caen, Créteil, Lyon, Nantes, Paris, Poitiers, Saint-Herblain, Suresnes

2012-04-03

Active, closed

A Prospective, Clinical Investigation of the Vanguard 360 Revision Knee

NCT01542580Osteoarthritis, Rheumatoid Arthritis, Traumatic Arthritis, Post Traumatic Deformity

Zimmer Biomet

Observational

255

Lyon

2012-03

Active, closed

Radical Fimbriectomy for Young BRCA Mutation Carriers

NCT01608074BRCA1 Mutation, BRCA2 Mutation, Hereditary Breast and Ovarian Cancer

Centre Oscar Lambret

Not applicable

123

Aix-en-Provence, Bordeaux, Clermont-Ferrand, Lille, Lyon, Marseille, Nice, Paris

2012-01-09

Recruiting

National Lymphangioleiomyomatosis Registry, France

NCT01484236Lymphangioleiomyomatosis

Vincent COTTIN

Observational

200

Lyon

2012-01

Recruiting

International (Pediatric) Peritoneal Biobank

NCT01893710Kidney Failure, Chronic, Peritoneal Dialysis Complication, Transplantation, Healthy

Heidelberg University

Observational

500

Lyon, Strasbourg

2011-02-01

Active, closed

Vismodegib in Treating Patients With Advanced Chondrosarcomas

NCT01267955Clear Cell Chondrosarcoma, Dedifferentiated Chondrosarcoma, Locally Advanced Chondrosarcoma, Mesenchymal Chondrosarcoma

DrugVismodegib

National Cancer Institute (NCI)

Phase 2

Bordeaux, Lille, Lyon, Marseille, Paris, Villejuif

2010-12-21

Recruiting

National Clinical and Biological Sarcoma Database : An Initiative of the French Sarcoma Group

NCT03978039Sarcoma

Institut Bergonié

Observational

150,000

Bordeaux, Lyon, Villejuif

2010-01-01

Active, closed

Radiation Therapy With Concomitant and Adjuvant Temozolomide Versus Radiation Therapy With Adjuvant PCV Chemotherapy in Patients With Anaplastic Glioma or Low Grade Glioma

NCT00887146Brain and Central Nervous System Tumors

DrugsProcarbazine·CCNU·Vincristine

Alliance for Clinical Trials in Oncology

Phase 3

305

Lyon, Nice, Villejuif

2009-09

Active, closed

Radiation Therapy in Treating Patients Receiving Hormone Therapy for Prostate Cancer (GETUG-AFU 18)

NCT00967863Prostate Cancer

UNICANCER

Not applicable

500

Angers, Bordeaux, Caen, Chambéry, Chambray-lès-Tours, Créteil, Lyon, Marseille

2008-10

Recruiting

Study of Bariatric Surgery

NCT02857179Bariatric Surgery

Hospices Civils de Lyon

Observational

5,000

Lyon

2007-11

Recruiting

Prognostic and Predictive Markers of Treatment Response in Patients With PAC.

NCT05776342Pancreatic Adenocarcinoma

GERCOR - Multidisciplinary Oncology Cooperative Group

Observational

4,050

Besançon, Clichy, Créteil, Lille, Lyon, Nancy, Paris, Poitiers

2003-01-01

Recruiting

Computerized Registry of Patients With Venous Thromboembolism (RIETE)

NCT02832245Venous Thromboembolism

Manuel Monreal

Observational

120,000

Besançon, Brest, Clermont-Ferrand, Colombes, Dijon, Lyon, Villeurbanne, Marseille

2001-03

By invitation

EuroSIDA - Clinical and Virological Outcome of European Patients Infected With HIV

NCT02699736HIV, Hepatitis B, Hepatitis C, AIDS

Copenhagen University Hospital, Rigshospitalet

Observational

23,000

Bordeaux, Lyon, Nice, Paris

1994-01

Recruiting

Clinical Database Associated With a Biological Banking Accessible to Initiate Epidemiological and Translational Collaborative Researches in Kidney Transplantation

NCT02900040Kidney Transplantation

Nantes University Hospital

Observational

30,000

Lyon, Montpellier, Nancy, Nice, Paris, Toulouse

1994-01

Recruiting

International Collaborative Gaucher Group (ICGG) Gaucher Disease Registry & Pregnancy Sub-registry

NCT00358943Gaucher Disease, Cerebroside Lipidosis Syndrome, Glucocerebrosidase Deficiency Disease, Glucosylceramide Beta-Glucosidase Deficiency Disease

Genzyme, a Sanofi Company

Observational

12,000

Besançon, Bordeaux, Brest, Bron, Caen, Clichy, Garches, Lyon

1991-04-01

Active, closed

RT or No RT Following Chemotherapy in Treating Patients With Stage III/IV Hodgkin's Disease

NCT00002462Lymphoma

DrugsProcarbazine hydrochloride·Vinblastine Sulfate·Bleomycin·Doxorubicin Hydrochloride

European Organisation for Research and Treatment of Cancer - EORTC

Phase 3

615

Bordeaux, Caen, Compiègne, Dijon, Lyon, Nice, Paris, Pierre-Bénite

1989-09

Cite this view

Priya Life Science (2026). Clinical trial register: studies with a French investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 27 October 2026. https://priyalifescience.com/clinical-trials-france/city/lyon?page=3

Query this register directly

GET /api/trials?country=in&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in France and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 9,697 studies in total at the last sync on 26 Oct 2026, 03:20 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 1,392 of those studies with a site in Lyon.

How many clinical trials are recruiting in Lyon?

784 of the 1,392 studies on this page are recruiting new participants as of the 26 Oct 2026, 03:20 UTC sync. A further 143 have not yet opened recruitment, 449 are active but closed to new participants, and 16 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and China registers.